Connecting via Winsock to STN

check again for the second author

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:43:19 ON 31 JUL 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:43:33 ON 31 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2003 HIGHEST RN 557055-78-4
DICTIONARY FILE UPDATES: 29 JUL 2003 HIGHEST RN 557055-78-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10019105.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:43:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   7584 TO ITERATE

 13.2% PROCESSED    1000 ITERATIONS                          7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       146463 TO   156897
PROJECTED ANSWERS:             624 TO     1498

L2             7 SEA SSS SAM L1

=> d scan
```

L2 7 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzoic acid, 2-(5-benzoyl-1H-benzimidazol-2-yl)-, [(3,4,5-trimethoxyphenyl)methylene]hydrazide (9CI)
MF C31 H26 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 7 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-[[[2-(3-pyridinyl)ethyl]amino]carbonyl]phenyl]- (9CI)
MF C28 H28 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=> s l1 ful
FULL SEARCH INITIATED 09:46:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 151969 TO ITERATE

100.0% PROCESSED  151969 ITERATIONS                          907 ANSWERS
SEARCH TIME: 00.00.08

L3          907 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             150.15     150.36

FILE 'CAPLUS' ENTERED AT 09:47:11 ON 31 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 31 Jul 2003  VOL 139 ISS 5
FILE LAST UPDATED: 30 Jul 2003  (20030730/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4          56 L3

=> d abs ibib hitstr 1-
YOU HAVE REQUESTED DATA FROM 56 ANSWERS - CONTINUE? Y/(N):y
```

L4 ANSWER 1 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB 2-Aryl-substituted benzimidazoles and imidazo[4,5]pyridines (shown as I; e.g. 2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide (II)) are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer. For I: W is COOH, -C(O)NHR1, or -SO2NHR1 (R1 is H or C1-4alkyl); Q is N or CH; Ra and Rb are H or halogen; Y, Y1 and Y2 = N and C-Rc with the proviso that 0, 1 or 2 of Y, Y1 and Y2 are N and at least 2 of Rc must be H; Rc = -H, -OH, -C1-6alkyl, -SCF3, halo, -CF3 and -OCF3; Z = O, S, SO, SO2, SO2NR2, NR2SO2, NH, CONR2, piperazinediyl or a covalent bond; R2 is H or C1-4alkyl; Ar1 is an arom. group as defined in the claims. IC50 values are reported for inhibition of human Cds1 checkpoint kinase by 103 examples of I, e.g. 3 nM for 2-[4-(4-chloro-3-trifluoromethylphenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide. Addnl. studies were (i) detn. of the effect of II on tumor cell line clonogenic survival, (ii) effect of II on tumor growth in murine xenograft models, (iii) detn. of the effect of 14 examples of I on radiation-induced apoptosis in isolated primary cells, and (iv) detn. of the effect of II on radiation-induced apoptosis in splenocytes in vivo. Although the methods of prepn. are not claimed, .apprx.100 example prepns. are included.

ACCESSION NUMBER: 2003:319709 CAPLUS
DOCUMENT NUMBER: 138:338144
TITLE: Preparation of 2-phenyl benzimidazoles and imidazo-[4,5]pyridines as Cds1/Chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
INVENTOR(S): Arienti, Kristen L.; Axe, Frank U.; Breitenbucher, J. Guy; Huang, Liming; Lee, Alice; McClure, Kelly J.
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032984	A1	20030424	WO 2002-US33371	20021018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-330304P P 20011019
OTHER SOURCE(S): MARPAT 138:338144
IT **516482-00-1P**, 2-[4-(Phenylcarbamoyl)phenyl]-1H-benzimidazole-5-carboxylic acid amide **516482-01-2P**, 2-[4-(4-Chlorophenylcarbamoyl)phenyl]-1H-benzimidazole-5-carboxylic acid amide **516482-02-3P**, 2-[4-[(4-Chlorophenyl)(methyl)carbamoyl]phenyl]-1H-benzimidazole-5-carboxylic acid amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzimidazoles and imidazopyridines as Cds1/Chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in treatment of cancer)
RN 516482-00-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[4-[(phenylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 516482-01-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[4-[[(4-chlorophenyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 516482-02-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[4-[[(4-chlorophenyl)methylamino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI

*STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepd. and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

ACCESSION NUMBER: 2003:203407 CAPLUS
DOCUMENT NUMBER: 138:238181
TITLE: Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: U.S. Pat. Appl. Publ., 406 pp., Cont.-in-part of Appl. No. PCT/JP00/09181.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003050320	A1	20030313	US 2001-939374	20010824
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001247550	A2	20010911	JP 2000-391904	20001225

PRIORITY APPLN. INFO.:
JP 1999-369008 A 19991227
WO 2000-JP9181 A2 20001222
JP 2000-391904 A 20001225
JP 2001-193786 A 20010626

OTHER SOURCE(S): MARPAT 138:238181
IT **347169-06-6P 347169-08-8P 347169-09-9P**
347169-10-2P 347169-11-3P 347169-12-4P
347169-13-5P 347169-14-6P 347169-15-7P
347169-16-8P 347169-17-9P 347169-18-0P
347169-19-1P 347169-20-4P 347169-21-5P
347169-22-6P 347169-23-7P 347169-24-8P
347169-25-9P 347169-26-0P 347169-27-1P
347169-28-2P 347169-29-3P 347169-30-6P

347169-31-7P 347169-32-8P 347169-33-9P
347169-34-0P 347169-35-1P 347169-36-2P
347169-37-3P 347169-38-4P 347169-39-5P
347169-40-8P 347169-41-9P 347169-42-0P
347169-43-1P 347169-44-2P 347169-45-3P
347169-46-4P 347169-47-5P 347169-48-6P
347169-49-7P 347169-50-0P 347169-51-1P
347169-52-2P 347169-53-3P 347169-54-4P
347169-55-5P 347169-56-6P 347169-57-7P
347169-58-8P 347169-59-9P 347169-60-2P
347169-61-3P 347169-62-4P 347169-63-5P
347169-64-6P 347169-65-7P 347169-86-2P
347169-87-3P 347169-88-4P 347169-89-5P
347169-90-8P 347169-91-9P 347169-92-0P
347169-93-1P 347169-94-2P 347169-95-3P
347169-96-4P 347169-97-5P 347169-98-6P
347169-99-7P 347170-00-7P 347170-01-8P
347170-02-9P 347170-03-0P 347170-04-1P
347170-05-2P 347170-06-3P 347170-07-4P
347170-08-5P 347170-09-6P 347170-10-9P
347170-12-1P 347170-13-2P 347170-14-3P
347170-15-4P 347170-16-5P 347170-17-6P
347170-18-7P 347170-19-8P 347170-20-1P
347170-21-2P 347170-22-3P 347170-23-4P
347170-24-5P 347170-25-6P 347170-26-7P
347170-27-8P 347170-28-9P 347170-29-0P
347170-30-3P 347170-31-4P 347170-32-5P
347170-33-6P 347170-34-7P 347170-35-8P
347170-36-9P 347170-37-0P 347170-38-1P
347170-39-2P 347170-40-5P 347170-41-6P
347170-42-7P 347170-43-8P 347170-44-9P
347170-45-0P 347170-46-1P 347170-47-2P
347170-48-3P 347170-49-4P 347170-50-7P
347170-51-8P 347170-52-9P 347170-53-0P
347170-54-1P 347170-55-2P 347170-56-3P
347170-57-4P 347170-58-5P 347170-59-6P
347170-60-9P 347170-61-0P 347170-62-1P
347170-64-3P 347170-65-4P 347170-66-5P
347170-67-6P 347170-68-7P 347170-69-8P
347170-70-1P 347170-71-2P 347170-72-3P
347170-73-4P 347170-74-5P 347170-75-6P
347170-79-0P 347170-80-3P 347170-81-4P
347170-82-5P 347170-83-6P 347170-84-7P
347170-85-8P 347170-86-9P 347170-87-0P
347170-88-1P 347170-89-2P 347170-90-5P
347170-91-6P 347170-92-7P 347170-93-8P
347170-94-9P 347170-95-0P 347170-96-1P
347170-97-2P 347170-98-3P 347170-99-4P
347171-00-0P 347171-01-1P 347171-02-2P
347171-03-3P 347171-04-4P 347171-05-5P
347171-06-6P 347171-07-7P 347171-08-8P
347171-09-9P 347171-10-2P 347171-11-3P
347171-12-4P 347171-13-5P 347171-14-6P
347171-15-7P 347171-16-8P 347171-17-9P
347171-18-0P 347171-19-1P 347171-20-4P
347171-21-5P 347171-22-6P 347171-23-7P
347171-24-8P 347171-25-9P 347171-26-0P
347171-27-1P 347171-28-2P 347171-29-3P
347171-30-6P 347171-31-7P 347171-32-8P
347171-33-9P 347171-34-0P 347171-35-1P

347171-36-2P 347171-37-3P 347171-38-4P
347171-39-5P 347171-40-8P 347171-41-9P
347171-42-0P 347171-43-1P 347171-44-2P
347171-45-3P 347171-46-4P 347171-47-5P
347171-48-6P 347171-49-7P 347171-50-0P
347171-51-1P 347171-52-2P 347171-53-3P
347171-54-4P 347171-55-5P 347171-56-6P
347171-57-7P 347171-58-8P 347171-59-9P
347171-60-2P 347171-61-3P 347171-62-4P
347171-63-5P 347171-64-6P 347171-65-7P
347171-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)

RN 347169-06-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[3-(methoxycarbonyl)phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-08-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[(1-ethylpropyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-09-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-10-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(2-fluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-11-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(3-fluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-12-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI



I



II

AB A method for identifying compds. binding to hepatitis C virus (HCV) RNA-dependent RNA polymerase is provided. HCV polymerase or an analog is contacted with a probe formula I, wherein A is O, S, N, NR1, or CR1, wherein R1 is defined as either a single or a double bond; R2 is selected from H, halogen, R21, OR21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 or NR22C(O)NR22, wherein R21 and each R22 is defined herein; B is NR3 or CR3, wherein R3 is defined herein; with the proviso that, when A is not N, then one of A or B is either CR1 or CR3, K is N or CR4, wherein R4 is defined herein; L is N or CR5, wherein R5 has the same definition as R4 defined above; M is N or CR7, wherein R7 has the same definition as R4 defined above;R5 is C(Y1)Z wherein Y1 is O or S; and Z is N(R6a)R6 or OR6, wherein R6a is H or alkyl or NR61R62 wherein R61 and R62 are defined herein; and R6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is wherein R7 and R8 and Q are as defined herein; Y2 is O or S; R9 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl, aryl, Het, (C1-6)alkyl-aryl or (C1-6)alkyl-Het, all of which optionally substituted with R90; or R9 is covalently bonded to either of R7 or R8 to form a 5- or 6-membered heterocycle; or a salt thereof; where the probe comprises a detectable label attached to any suitable position, whereby said probe binds to an HCV polymerase or an analog thereof and is capable of being displaced by an inhibitor thereof. The assocn. of a specific probe with the HCV NS5B polymerase can be monitored and quantified directly by a change in the intrinsic spectral properties of a tagged or un-tagged NS5B protein and/or by a change i the intrinsic spectral properties of a specific probe. A direct measurement of inhibitor-NS5B assocn. can also be achieved by immobilizing one of these two components on a matrix and measuring assocn. through plasma-resonance detection technol. An assay that quantifies probe-NS5B complex assocn. may also incorporate a photo-reactive label (such as phenyl-azide or benzophenone) on the probe and measure the amt. of label irreversibly bound to the NS5B adduct following photo-activation of the probe. Thus, titrn. of fluorescein-labeled probe II (FL = 5-thiocarbonylaminofluorescein) with the enzyme was measured with excitation wavelength at 493 nm and emission monitored at 530 nm, indicating a Kd value of 6 nM, which is .gtoreq.100-fold higher for HCV polymerase than

obtained with the GBV-B polymerase. A major advantage of the direct binding assay is that different affinities for the primer/template RNA substrate with N-terminal tag His-NS5B.DELTA.21 and C-terminal tag NS5B.DELTA.21-His are reconciled by relatively similar Kd values that individual inhibitors display with the two different HCV polymerases.

ACCESSION NUMBER: 2003:133484 CAPLUS
DOCUMENT NUMBER: 138:165718
TITLE: Probes for direct binding assay for identifying inhibitors of hepatitis C virus RNA-dependent RNA polymerase
INVENTOR(S): Kukolj, George; Beaulieu, Pierre L.; McKercher, Ginette
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014377	A2	20030220	WO 2002-CA1214	20020805
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003108862	A1	20030612	US 2002-211455	20020802

PRIORITY APPLN. INFO.: US 2001-310272P P 20010807
OTHER SOURCE(S): MARPAT 138:165718

IT **497844-93-6P 497844-96-9P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(probes for direct binding assay for identifying inhibitors of hepatitis C virus RNA-dependent RNA polymerase)

RN 497844-93-6 CAPLUS
CN L-Tryptophan, 5-(carboxymethoxy)-N-[[2-[4-[[[2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]ethyl]amino]carbonyl]phenyl]-1-phenyl-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 497844-96-9 CAPLUS
CN L-Tryptophan, 5-(carboxymethoxy)-N-[[2-[4-[[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]amino]carbonyl]phenyl]-1-phenyl-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L4 ANSWER 4 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



II

AB RZZ1R5 [I; R = CONR1R2 and R5 = NR3R4 or CONR3R4 or R = NR1COR2 and R5 = CONR3R4; R1,R2 = H, alkyl, (un)substituted (hetero)aryl, etc.; R3,R4 = H, alkyl, (hetero)aryl, alkanoyl, aroyl, etc.; Z = (un)substituted benzimidazole-n,2-diyl; Z1 = (un)substituted phenylene; n = 4-7] were prepd. Thus, 3,4-(H2N)2C6H3CO2H was cyclocondensed with 4-(O2N)C6H4CHO and the product amidated by cyclohexylamine to give, after redn. and amidation, title compd. II. Data for biol. activity of 1 I were given.

ACCESSION NUMBER: 2002:716082 CAPLUS
DOCUMENT NUMBER: 137:232653
TITLE: Preparation of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors
INVENTOR(S): Sircar, Jagadish C.; Richards, Mark L.; Major, Michael W.
PATENT ASSIGNEE(S): Avanir Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 213 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072090	A1	20020919	WO 2002-US6801	20020228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002132808	A1	20020919	US 2002-90044	20020227

PRIORITY APPLN. INFO.: US 2001-275260P P 20010312
US 2002-90044 A 20020227
OTHER SOURCE(S): MARPAT 137:232653
IT **459806-84-9P 459806-85-0P 459806-86-1P**
459806-87-2P 459806-88-3P 459806-89-4P
459806-90-7P 459806-91-8P 459806-92-9P
459806-93-0P 459806-94-1P 459806-95-2P
459806-96-3P 459806-97-4P 459806-98-5P
459806-99-6P 459807-00-2P 459807-01-3P

459807-02-4P 459807-03-5P 459807-04-6P
459807-05-7P 459807-06-8P 459807-07-9P
459807-08-0P 459807-09-1P 459807-10-4P
459807-11-5P 459807-12-6P 459807-13-7P
459807-14-8P 459807-15-9P 459807-16-0P
459807-17-1P 459807-18-2P 459807-19-3P
459807-20-6P 459807-21-7P 459807-22-8P
459807-23-9P 459807-24-0P 459807-25-1P
459807-26-2P 459807-27-3P 459807-28-4P
459807-29-5P 459807-30-8P 459807-31-9P
459807-32-0P 459807-33-1P 459807-34-2P
459807-35-3P 459807-36-4P 459807-37-5P
459807-38-6P 459807-39-7P 459807-40-0P
459807-41-1P 459807-42-2P 459807-43-3P
459807-44-4P 459807-45-5P 459807-46-6P
459807-47-7P 459807-48-8P 459807-49-9P
459807-50-2P 459807-51-3P 459807-52-4P
459807-53-5P 459807-54-6P 459807-55-7P
459807-56-8P 459807-57-9P 459807-58-0P
459807-59-1P 459807-60-4P 459807-61-5P
459807-62-6P 459807-63-7P 459807-64-8P
459807-65-9P 459807-66-0P 459807-67-1P
459807-68-2P 459807-69-3P 459807-70-6P
459807-71-7P 459807-72-8P 459807-73-9P
459807-74-0P 459807-75-1P 459807-76-2P
459807-77-3P 459807-78-4P 459807-79-5P
459807-80-8P 459807-81-9P 459807-82-0P
459807-83-1P 459807-84-2P 459807-85-3P
459807-86-4P 459807-87-5P 459807-88-6P
459807-89-7P 459807-90-0P 459807-91-1P
459807-92-2P 459807-93-3P 459807-94-4P
459807-95-5P 459807-96-6P 459807-97-7P
459807-98-8P 459807-99-9P 459808-00-5P
459808-01-6P 459808-02-7P 459808-03-8P
459808-04-9P 459808-05-0P 459808-06-1P
459808-07-2P 459808-08-3P 459808-09-4P
459808-10-7P 459808-11-8P 459808-12-9P
459808-13-0P 459808-14-1P 459808-15-2P
459808-16-3P 459808-17-4P 459808-18-5P
459808-19-6P 459808-20-9P 459808-21-0P
459808-22-1P 459808-23-2P 459808-24-3P
459808-25-4P 459808-26-5P 459808-27-6P
459808-28-7P 459808-29-8P 459808-30-1P
459808-31-2P 459808-32-3P 459808-33-4P
459808-34-5P 459808-35-6P 459808-36-7P
459808-37-8P 459808-38-9P 459808-39-0P
459808-40-3P 459808-41-4P 459808-42-5P
459808-43-6P 459808-44-7P 459808-45-8P
459808-46-9P 459808-47-0P 459808-48-1P
459808-49-2P 459808-50-5P 459808-51-6P
459808-52-7P 459808-53-8P 459808-54-9P
459808-55-0P 459808-56-1P 459808-57-2P
459808-58-3P 459808-59-4P 459808-60-7P
459808-61-8P 459808-62-9P 459808-63-0P
459808-64-1P 459808-65-2P 459808-66-3P
459808-67-4P 459808-68-5P 459808-69-6P
459808-70-9P 459808-71-0P 459808-72-1P
459808-73-2P 459808-74-3P 459808-75-4P
459808-76-5P 459808-77-6P 459808-78-7P
459808-79-8P 459808-80-1P 459808-81-2P

459808-82-3P 459808-83-4P 459808-84-5P
459808-85-6P 459808-86-7P 459808-87-8P
459808-88-9P 459808-89-0P 459808-90-3P
459808-91-4P 459808-92-5P 459808-93-6P
459808-94-7P 459808-95-8P 459808-96-9P
459808-97-0P 459808-98-1P 459808-99-2P
459809-00-8P 459809-01-9P 459809-02-0P
459809-03-1P 459809-04-2P 459809-05-3P
459809-06-4P 459809-07-5P 459809-08-6P
459809-09-7P 459809-10-0P 459809-11-1P
459809-12-2P 459809-13-3P 459809-14-4P
459809-15-5P 459809-16-6P 459809-17-7P
459809-18-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(carboxamidophenyl)benzimidazole-5-carboxamides and analogs as IgE and cell proliferation inhibitors)

RN 459806-84-9 CAPLUS
CN Benzamide, N-cyclohexyl-4-[5-[(cyclohexylcarbonyl)amino]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 459806-85-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[2-[4-[(cyclohexylamino)carbonyl]phenyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 459806-86-1 CAPLUS
CN Benzamide, N-cyclohexyl-4-[5-[[(2-methylcyclohexyl)carbonyl]amino]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI



I



II



III



IV

AB This invention discloses the prepn. of title compds. I and II, their pharmaceutically acceptable salts, and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP) [wherein: A = N, C, CH2, CH; B = C, N, NH, S, SO, SO2; X = C, CH, N; Y = C, N; Z = C, CH2, N, CO; provided that at least one of X, Y, or Z is N; R1, R2, R3, R5 when present are optionally or independently = H, OH, :O, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, amine, COR8 (R8 = H, OH, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl), OR6, NR6R7 (R6, R7 independently = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl); R1, R2, R3, R5 optionally form ring through a straight or branched C1-4alkyl which may addnl. contain 1-2 double or triple bonds; R4 = 1-3 of H, halo, or alkyl; with proviso that when A, X, or Z = C, then R1, R2, R3 when present may also independently = halogen, CN, O; R9, R10, R11, R12 optionally or independently = H, halogen, amino, OH, halo-amine, O-alkyl, O-aryl, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, carboxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, COR8; R13 = 1-3 of H, halogen, alkoxy, alkyl]. For example, cyclocondensation of formylindazole III (prepd. from Me indole-4-carboxylate and NaNO2/AcOH), with hydrazine provided claimed benzoazulenone IV as a white solid. Benzoazulenone IV inhibited human recombinant PARP at an IC50 of 0.018 .mu.M. PARP IC50 inhibition studies for an addnl. 156 examples are provided, ranging in values from 0.01 to 20 .mu.M. Biol. data are provided for the in vivo treatment of focal cerebral ischemia and gout via PARP inhibition with selected compds. II. The present invention is believed to protect cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide through inhibition of PARP activity.

ACCESSION NUMBER: 2002:428911 CAPLUS
DOCUMENT NUMBER: 137:6205
TITLE: Preparation of benzazepinones, isoquinolinones and

related compounds as inhibitors of poly(ADP-ribose) polymerase (PARP) for the prevention and/or treatment of tissue damage from cell trauma or cell death due to necrosis or apoptosis.

INVENTOR(S): Ferraris, Dana V.; Li, Jia-He; Kalish, Vincent J.; Zhang, Jie

PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044183	A2	20020606	WO 2001-US44815	20011130
WO 2002044183	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002036521	A5	20020611	AU 2002-36521	20011130
US 2003022883	A1	20030130	US 2001-996776	20011130

PRIORITY APPLN. INFO.:

US 2000-250132P	P	20001201
US 2001-310274P	P	20010809
WO 2001-US44815	W	20011130

OTHER SOURCE(S): MARPAT 137:6205

IT **433726-35-3P 433726-37-5P 433727-34-5P**
433727-35-6P 433727-36-7P 433727-37-8P
433727-38-9P 433727-39-0P 433727-40-3P
433727-41-4P 433727-42-5P 433727-43-6P
433727-44-7P 433727-45-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzazepinones, isoquinolinones and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))

RN 433726-35-3 CAPLUS

CN Piperazine, 1-methyl-4-[3-(4,5,6,7-tetrahydro-7-oxoimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



RN 433726-37-5 CAPLUS
CN Benzamide, N-[3-(dimethylamino)propyl]-N-methyl-3-(4,5,6,7-tetrahydro-7-oxoimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 433727-34-5 CAPLUS
CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-(4,5,6,7-tetrahydro-7-oxoimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 433727-35-6 CAPLUS
CN Benzamide, N-[2-(1-pyrrolidinyl)ethyl]-3-(4,5,6,7-tetrahydro-7-oxoimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI



I

AB The compds. I [ring A, ring B = (un)substituted arom. ring; X = NR0, S, O; R0 = H, lower alkyl; Y = NR1R2, CONR1'R2', C(OH)R1''R2'', (un)substituted (un)satd. 5- to 7-membered heterocycle; R1 = (un)substituted lower alkyl, alkenyl, alkynyl; R2 = org. group excluding lower alkyl; R1R2 may form heterocycle; R1', R2' = (un)substituted lower alkyl; R1'R2' may form heterocycle; R1'', R2'' = (un)substituted lower alkyl] or their pharmaceutically acceptable salts are prepd. The compds. are useful for anti-inflammatory agents, antirheumatic agents, and agents for bone regeneration. 2-(5,6-Dichloro-1H-imidazol-2-yl)-N-methylaniline (2.06 g) was reacted with acetyl chloride in pyridine at 25.degree. for 1 h to give 630 mg N-[2-(5,6-dichloro-1H-benzimidazol-2-yl)phenyl]-N-methylacetamide showing 66% inhibition of osteoclast differentiation in vitro.

ACCESSION NUMBER: 2002:422943 CAPLUS
DOCUMENT NUMBER: 137:6177
TITLE: Preparation of phenylbenzimidazoles as osteoclast differentiation induction inhibitors and osteoclast inhibitors
INVENTOR(S): Nakahira, Hiroyuki; Horiuchi, Yoshihiro
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 87 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002161084	A2	20020604	JP 2000-360964	20001128

PRIORITY APPLN. INFO.: JP 2000-360964 20001128
OTHER SOURCE(S): MARPAT 137:6177

IT **433299-24-2P 433299-26-4P 433299-28-6P**
433299-30-0P 433299-31-1P 433299-32-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylbenzimidazoles as osteoclast differentiation induction inhibitors and osteoclast inhibitors)

RN 433299-24-2 CAPLUS
CN Benzamide, 2-(5,6-dichloro-1H-benzimidazol-2-yl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 433299-26-4 CAPLUS
CN Piperidine, 1-[2-(5,6-dichloro-1H-benzimidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



RN 433299-28-6 CAPLUS
CN Pyrrolidine, 1-[2-(5,6-dichloro-1H-benzimidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



RN 433299-30-0 CAPLUS
CN Benzamide, 2-(5,6-dichloro-1H-benzimidazol-2-yl)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 433299-31-1 CAPLUS
CN Benzamide, 2-(5,6-dichloro-1H-benzimidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 433299-32-2 CAPLUS
CN Benzamide, 2-(5,6-dichloro-1H-benzimidazol-2-yl)-N-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI



I



I

AB The starting compd. 5-nitrobenzimidazol-2'-yl-o-benzoyl hydrazide, on treatment with arom. aldehydes yielded the corresponding benzal-(5'-nitrobenzimidazol-2'-yl-o-benzolyl) hydrazines I(R = Ph, 2-ClC6H4, 4-HOC6H4, etc.). The heterocyclization of I with thioglycolic acid and thiolactic acid furnished the corresponding 2-aryl-3-(5'-nitrobenzimidazol-2' -yl-o-benzamido) -5-H-4-thiazolidinones (3a-o) and 2-aryl-3-(5'-nitrobenzimidazol-2'-yl-o-benzamido)-5-methyl-4-thiazolidinones II (X = CO; R1 = H, Me, resp.). The compds. were screened for their antitubercular activity against Mycobacterium tuberculosis H37 Rv.

ACCESSION NUMBER: 2002:130859 CAPLUS
DOCUMENT NUMBER: 137:337812
TITLE: Synthesis of some 4-thiazolidinones as potential antitubercular agents
AUTHOR(S): Joshi, Dharti G.; Oza, Haresh B.; Parekh, Hansa H.
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Indian Journal of Heterocyclic Chemistry (2001), 11(2), 145-148
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Prof. R. S. Varma
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **474301-77-4P 474301-78-5P 474301-79-6P**
474301-80-9P 474301-81-0P 474301-82-1P
474301-83-2P 474301-84-3P 474301-85-4P
474301-86-5P 474301-87-6P 474301-88-7P

474301-89-8P 474301-90-1P 474301-91-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzimidazoles and thiazolidinones as potential antitubercular agents)

RN 474301-77-4 CAPLUS
CN Benzoic acid, 2-(5-nitro-1H-benzimidazol-2-yl)-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 474301-78-5 CAPLUS
CN Benzoic acid, 2-(5-nitro-1H-benzimidazol-2-yl)-, [(2-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 474301-79-6 CAPLUS
CN Benzoic acid, 2-(5-nitro-1H-benzimidazol-2-yl)-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 474301-80-9 CAPLUS
CN Benzoic acid, 2-(5-nitro-1H-benzimidazol-2-yl)-, [(2,4-dichlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H , alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1], were prepd. Thus, Me 3-amino-4-cyclohexylaminobenzoate (prepn. given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was sapond. with aq. NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 .mu.M.

ACCESSION NUMBER: 2002:51438 CAPLUS
DOCUMENT NUMBER: 136:118447
TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6448281	B2	20020910		
EP 1301487	A2	20030416	EP 2001-951274	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 6479508	B1	20021112	US 2001-995099	20011127
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2000-216084P P 20000706
US 2001-274374P P 20010308
US 2001-281343P P 20010405
US 2001-898297 A3 20010703
WO 2001-CA989 W 20010704

OTHER SOURCE(S): MARPAT 136:118447

IT **390810-27-2P 390814-80-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390810-27-2 CAPLUS

CN L-Tryptophan, 5-(carboxymethoxy)-N-[[1-cyclohexyl-2-[4-[[[2-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]ethyl]amino]carbonyl]phenyl]-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 390814-80-9 CAPLUS
CN L-Tryptophan, 5-(carboxymethoxy)-N-[[1-cyclohexyl-2-[4-[[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]amino]carbonyl]phenyl]-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



ANSWER 9 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The vacuolar proton pump (V-ATPase) located on the plasma membrane of the osteoclast is a potential mol. target for the discovery of novel bone antiresorptive agents useful for the treatment of osteoporosis. In order to design novel compds. able to selectively inhibit the osteoclast V-ATPase we firstly identified the minimal structural requirements of bafilomycin A1, a macrolide antibiotic which potently inhibits all V-ATPases. This information allowed the design of 2-(indole)pentadienamide derivs. whose optimization led to a novel class of potent inhibitors that demonstrated a high degree of selectivity for the osteoclast V-ATPase. The most interesting deriv., SB-242784, was able to inhibit bone resorption by human osteoclasts in vitro and to completely prevent ovariectomy-induced bone loss in rats when administered orally at 10 mg kg-1 day-1. Structure activity relationships of this class of compds. were investigated further by replacing the 2,4-pentadienoyl chain with suitable spacers able to maintain the correct orientation and distance between the indole ring and the amide moiety.

ACCESSION NUMBER: 2001:516943 CAPLUS
DOCUMENT NUMBER: 135:298171
TITLE: Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase
AUTHOR(S): Farina, Carlo; Gagliardi, Stefania; Nadler, Guy; Morvan, Marcel; Parini, Carlo; Belfiore, Pietro; Visentin, Luciano; Gowen, Maxine
CORPORATE SOURCE: SmithKline Beecham SpA, Milan, 20021, Italy
SOURCE: Farmaco (2001), 56(1-2), 113-116
CODEN: FRMCE8; ISSN: 0014-827X
PUBLISHER: Elsevier Science S.A.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **316809-79-7 316809-81-1**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure activity relationships of bone antiresorptive agents that inhibit osteoclast vacuolar H+-ATPase)

RN 316809-79-7 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-81-1 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C8 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepd. The benzimidazole deriv. II in vitro showed IC50 of 0.011 .mu.M against hepatitis C virus polymerase. A formulation is given.

ACCESSION NUMBER: 2001:489367 CAPLUS
DOCUMENT NUMBER: 135:76874
TITLE: Preparation of heterocyclic compounds as remedies for hepatitis C
INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1162196 A1 20011212 EP 2000-987728 20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 2000008525 A 20020102 BR 2000-8525 20001222
NZ 514403 A 20021025 NZ 2000-514403 20001222
NO 2001004134 A 20011022 NO 2001-4134 20010824
US 2003050320 A1 20030313 US 2001-939374 20010824

PRIORITY APPLN. INFO.: JP 1999-369008 A 19991227
WO 2000-JP9181 W 20001222
JP 2000-391904 A 20001225
JP 2001-193786 A 20010626

OTHER SOURCE(S): MARPAT 135:76874

IT **347169-06-6P 347169-08-8P 347169-09-9P**
347169-10-2P 347169-11-3P 347169-12-4P
347169-13-5P 347169-14-6P 347169-15-7P
347169-16-8P 347169-17-9P 347169-18-0P
347169-19-1P 347169-20-4P 347169-21-5P
347169-22-6P 347169-23-7P 347169-24-8P
347169-25-9P 347169-26-0P 347169-27-1P
347169-28-2P 347169-29-3P 347169-30-6P
347169-31-7P 347169-32-8P 347169-33-9P
347169-34-0P 347169-35-1P 347169-36-2P
347169-37-3P 347169-38-4P 347169-39-5P
347169-40-8P 347169-41-9P 347169-42-0P
347169-43-1P 347169-44-2P 347169-45-3P
347169-46-4P 347169-47-5P 347169-48-6P
347169-49-7P 347169-50-0P 347169-51-1P
347169-52-2P 347169-53-3P 347169-54-4P
347169-55-5P 347169-56-6P 347169-57-7P
347169-58-8P 347169-59-9P 347169-60-2P
347169-61-3P 347169-62-4P 347169-63-5P
347169-64-6P 347169-65-7P 347169-86-2P
347169-87-3P 347169-88-4P 347169-89-5P
347169-90-8P 347169-91-9P 347169-92-0P
347169-93-1P 347169-94-2P 347169-95-3P
347169-96-4P 347169-97-5P 347169-98-6P
347169-99-7P 347170-00-7P 347170-01-8P
347170-02-9P 347170-03-0P 347170-04-1P
347170-05-2P 347170-06-3P 347170-07-4P
347170-08-5P 347170-09-6P 347170-10-9P
347170-12-1P 347170-13-2P 347170-14-3P
347170-15-4P 347170-16-5P 347170-17-6P
347170-18-7P 347170-19-8P 347170-20-1P
347170-21-2P 347170-22-3P 347170-23-4P
347170-24-5P 347170-25-6P 347170-26-7P
347170-27-8P 347170-28-9P 347170-29-0P
347170-30-3P 347170-31-4P 347170-32-5P
347170-33-6P 347170-34-7P 347170-35-8P
347170-36-9P 347170-37-0P 347170-38-1P
347170-39-2P 347170-40-5P 347170-41-6P
347170-42-7P 347170-43-8P 347170-44-9P
347170-45-0P 347170-46-1P 347170-47-2P
347170-48-3P 347170-49-4P 347170-50-7P

347170-51-8P 347170-52-9P 347170-53-0P
347170-54-1P 347170-55-2P 347170-56-3P
347170-57-4P 347170-58-5P 347170-59-6P
347170-60-9P 347170-61-0P 347170-62-1P
347170-64-3P 347170-65-4P 347170-66-5P
347170-67-6P 347170-68-7P 347170-69-8P
347170-70-1P 347170-71-2P 347170-72-3P
347170-73-4P 347170-74-5P 347170-75-6P
347170-79-0P 347170-80-3P 347170-81-4P
347170-82-5P 347170-83-6P 347170-84-7P
347170-85-8P 347170-86-9P 347170-87-0P
347170-88-1P 347170-89-2P 347170-90-5P
347170-91-6P 347170-92-7P 347170-93-8P
347170-94-9P 347170-95-0P 347170-96-1P
347170-97-2P 347170-98-3P 347170-99-4P
347171-00-0P 347171-01-1P 347171-02-2P
347171-03-3P 347171-04-4P 347171-05-5P
347171-06-6P 347171-07-7P 347171-08-8P
347171-09-9P 347171-10-2P 347171-11-3P
347171-12-4P 347171-13-5P 347171-14-6P
347171-15-7P 347171-16-8P 347171-17-9P
347171-18-0P 347171-19-1P 347171-20-4P
347171-21-5P 347171-22-6P 347171-23-7P
347171-24-8P 347171-25-9P 347171-26-0P
347171-27-1P 347171-28-2P 347171-29-3P
347171-30-6P 347171-31-7P 347171-32-8P
347171-33-9P 347171-34-0P 347171-35-1P
347171-36-2P 347171-37-3P 347171-38-4P
347171-39-5P 347171-40-8P 347171-41-9P
347171-42-0P 347171-43-1P 347171-44-2P
347171-45-3P 347171-46-4P 347171-47-5P
347171-48-6P 347171-49-7P 347171-50-0P
347171-51-1P 347171-52-2P 347171-53-3P
347171-54-4P 347171-55-5P 347171-56-6P
347171-57-7P 347171-58-8P 347171-59-9P
347171-60-2P 347171-61-3P 347171-62-4P
347171-63-5P 347171-64-6P 347171-65-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic compds. as remedies for hepatitis C)

RN 347169-06-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[3-(methoxycarbonyl)phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-08-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[(1-

ethylpropyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-09-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-10-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(2-fluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 347169-11-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[[(3-fluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI



I



II



III

AB Some 1H-benzimidazole-carboxamide derivs. were prepd. and their antimicrobial activities against Staphylococcus aureus, Escherichia coli, and Candida albicans evaluated. Compds. I, II, and III exhibited the best activity against C. albicans.

ACCESSION NUMBER: 2001:412102 CAPLUS
DOCUMENT NUMBER: 135:177890
TITLE: Synthesis and antimicrobial activity of some new 2-phenyl-N-substituted carboxamido-1H-benzimidazole derivatives
AUTHOR(S): Goker, Hakan; Tuncbilek, Meral; Suzen, Sibel; Kus, Canan; Altanlar, Nurten
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, 06100, Turk.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (2001), 334(5), 148-152
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:177890

IT **355022-47-8P 355022-48-9P 355022-49-0P 355022-50-3P 355022-51-4P 355022-52-5P 355022-53-6P 355022-54-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antimicrobial activity of new 2-phenyl-N-substituted carboxamido-1H-benzimidazole derivs.)

RN 355022-47-8 CAPLUS
CN Benzamide, 4-[1-butyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 355022-48-9 CAPLUS
CN Benzamide, 4-[5-cyano-1-(1-methylethyl)-1H-benzimidazol-2-yl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 355022-49-0 CAPLUS
CN Benzamide, 4-(5-cyano-1-propyl-1H-benzimidazol-2-yl)-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 355022-50-3 CAPLUS
CN Benzamide, 4-[1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)





RN 355022-51-4 CAPLUS
CN Benzamide, 4-[5-chloro-1-[(4-chlorophenyl)methyl]-1H-benzimidazol-2-yl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)





RN 355022-52-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[(4-chlorophenyl)methyl]-2-[4-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 355022-53-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-[(4-chlorophenyl)methyl]-2-[4-[[(2-pyridinylmethyl)amino]carbonyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 355022-54-7 CAPLUS
CN Benzamide, 4-[1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)-1H-benzimidazol-2-yl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
AB The title compds. were prepd. and their bactericidal, fungicidal, and antitubercular activities detd.

ACCESSION NUMBER: 2001:230886 CAPLUS
DOCUMENT NUMBER: 135:5563
TITLE: N-Aryl-o-(5'-benzoylbenzimidazol-2'-yl)benzamides
AUTHOR(S): Doshi, Rajeev; Kagthara, Preeti; Parekh, H. H.
CORPORATE SOURCE: Chemistry Department, Saurashtra University, Rajkot, 360 005, India
SOURCE: Journal of the Institution of Chemists (India) (2000), 72(4), 140-141
CODEN: JOICA7; ISSN: 0020-3254
PUBLISHER: Institution of Chemists (India)
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **341997-38-4P 341997-39-5P 341997-40-8P**
341997-41-9P 341997-42-0P 341997-43-1P
341997-44-2P 341997-45-3P 341997-46-4P
341997-47-5P 341997-48-6P 341997-49-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of aryl(benzoylbenzimidazolyl)benzamides and their bactericidal, fungicidal, and antitubercular activities)

RN 341997-38-4 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 341997-39-5 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 341997-40-8 CAPLUS

CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(2,4-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 341997-41-9 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(3,4-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 341997-42-0 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(3,5-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 341997-43-1 CAPLUS

CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-dodecyl- (9CI) (CA INDEX NAME)



RN 341997-44-2 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-octadecyl- (9CI) (CA INDEX NAME)



RN 341997-45-3 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 341997-46-4 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 341997-47-5 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 341997-48-6 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 341997-49-7 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB .beta.-Lactams have attracted considerable attention in view of their strong antibiotic activity. Taking this into consideration, the prepn. of 2-azetidinones, e.g. I, using a well known acid chloride imine reaction have been undertaken by condensation of a Schiff's base, e.g. II, and chloroacetyl chloride in the presence of triethylamine. The constitution of the products was established by elemental analyses, IR and PMR spectral study.

ACCESSION NUMBER: 2001:230885 CAPLUS
DOCUMENT NUMBER: 135:5468
TITLE: Azetidinones as bioactive compounds derived from benzimidazole
AUTHOR(S): Doshi, Rajeev; Kagthara, Preeti; Parekh, H. H.
CORPORATE SOURCE: Chemistry Department, Saurashtra University, Rajkot, 360 005, India
SOURCE: Journal of the Institution of Chemists (India) (2000), 72(4), 138-139
CODEN: JOICA7; ISSN: 0020-3254
PUBLISHER: Institution of Chemists (India)
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:5468
IT **340984-29-4P 340984-30-7P 340984-31-8P**
340984-32-9P 340984-33-0P 340984-34-1P
340984-35-2P 340984-36-3P 340984-37-4P
340984-38-5P 340984-39-6P 340984-40-9P
340984-41-0P 340984-42-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(azetidinones as bioactive compds. derived from benzimidazole)
RN 340984-29-4 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-(3-chloro-2-oxo-4-phenyl-1-azetidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compds. and their physiol. acceptable salts and prodrugs. In particular, compds. I, II, and III are claimed [wherein: Q = CF3SO2, CF3SO2NR3, CF3SO2R4, or CF3SO2N(R3)R4; R1 = H, alkyl, haloalkyl, cyano, CO2H or derivs., halo, OH or derivs., NH2 or derivs., etc.; R2 = H, groups similar to R1; R3 = H, (un)substituted alkoxy, acyl, or alkyl; R4 = (un)substituted CH2; n = 0-3; B = atoms to complete (un)substituted fused aryl, carbocyclyl, heteroaryl, or heterocyclyl ring; A1 = (un)substituted and/or heteroatom-replaced linkage of 2-8 atoms length; A2 = similar linkage of 0-6 atoms]. These compds. are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase (PTP), and therefore are expected to be useful in the prevention and treatment of disorders assocd. with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurol. degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compds. contg. fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell. Over 100 compds. were prepd., and most were assayed against selected PTPs. For example, etherification of Me 4-(2-hydroxyethoxy)benzoic acid Me ester with 2-nitro-4-(trifluoromethylsulfonyl)chlorobenzene using NaH, and hydrolysis with HCl in aq. THF-EtOH, gave title compd. IV. This compd. had IC50 values as follows (.mu.M): PTP 1B = 1.5, PTP MEG2 = 1.5, PTP .alpha. = 22.2.

ACCESSION NUMBER: 2001:167962 CAPLUS
DOCUMENT NUMBER: 134:222529
TITLE: Preparation of aromatic trifluoromethylsulfonyl and trifluoromethylsulfonamido compounds as phosphate mimics and phosphatase inhibitors and methods of treatment
INVENTOR(S): Huang, Ping; Wei, Chung Chen; Tang, Peng Cho; Liang, Chris; Ramphal, John; Jallal, Bahija; Blitz, John; Li, Sharon; Mattson, Matthew Neil; Mcahon, Gerald; Koenig, Marcel
PATENT ASSIGNEE(S): Sugen, Inc., USA; et al.
SOURCE: PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016097	A1	20010308	WO 2000-US23293	20000825

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1212296 A1 20020612 EP 2000-961360 20000825

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003508382 T2 20030304 JP 2001-519667 20000825

US 6596772 B1 20030722 US 2000-645879 20000825

PRIORITY APPLN. INFO.: US 1999-150970P P 19990827

US 1999-165365P P 19991112

WO 2000-US23293 W 20000825

OTHER SOURCE(S): MARPAT 134:222529

IT **329317-63-7P**, 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzimidazol-2-yl)-N-pyridin-4-ylbenzamide **329317-64-8P**, 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzimidazol-2-yl)-N-(4-methoxyphenyl)benzamide **329317-65-9P**, 3-[4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzimidazol-2-yl)benzoylamino]benzoic acid ethyl ester **329317-66-0P**, 4-(1-Ethyl-5-trifluoromethanesulfonyl-1H-benzimidazol-2-yl)-N-(2-pyrrolidin-1-ylethyl)benzamide **329317-67-1P**, N-Ethyl-4-(1-ethyl-5-trifluoromethanesulfonyl-1H-benzimidazol-2-yl)benzamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of arom. trifluoromethylsulfonyl and trifluoromethylsulfonamido compds. as phosphate mimics and phosphatase inhibitors)

RN 329317-63-7 CAPLUS

CN Benzamide, 4-[1-ethyl-5-[(trifluoromethyl)sulfonyl]-1H-benzimidazol-2-yl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 329317-64-8 CAPLUS

CN Benzamide, 4-[1-ethyl-5-[(trifluoromethyl)sulfonyl]-1H-benzimidazol-2-yl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 329317-65-9 CAPLUS

CN Benzoic acid, 3-[[4-[1-ethyl-5-[(trifluoromethyl)sulfonyl]-1H-benzimidazol-2-yl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 329317-66-0 CAPLUS
CN Benzamide, 4-[1-ethyl-5-[(trifluoromethyl)sulfonyl]-1H-benzimidazol-2-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 329317-67-1 CAPLUS
CN Benzamide, N-ethyl-4-[1-ethyl-5-[(trifluoromethyl)sulfonyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB The title compds. [I; X = O, S, NH, etc.; Y, Z = N, CH, CR1, CR2; A = (un)substituted aryl, heterocyclyl; Ra = CONR3R4 (wherein R3, R4 = H, alkyl, cycloalkyl, etc.); R1, R2 = H, OH, NH2, etc.], useful in the treatment and/or prophylaxis of diseases assocd. with over activity of osteoclasts in mammals, were prepd. E.g., a multi-step synthesis of the benzimidazole II was given. The compds. I are able to inhibit bafilomycin-sensitive ATPase of human osteoclasts in a range from 2 nM to 15 .mu.M.

ACCESSION NUMBER: 2001:12425 CAPLUS
DOCUMENT NUMBER: 134:86246
TITLE: Preparation of azolylbenzamides and analogues for treating osteoporosis
INVENTOR(S): Farina, Carlo; Gagliardi, Stefania; Rahman, Shahzad Sharooq
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK; Smithkline Beecham S.P.A.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000587	A1	20010104	WO 2000-EP5881	20000623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1187813 A1 20020320 EP 2000-947877 20000623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2003503390 T2 20030128 JP 2001-506997 20000623
PRIORITY APPLN. INFO.: GB 1999-14825 A 19990624
WO 2000-EP5881 W 20000623
OTHER SOURCE(S): MARPAT 134:86246
IT **316809-76-4P 316809-77-5P 316809-78-6P**
316809-79-7P 316809-80-0P 316809-81-1P
316809-82-2P 316809-83-3P 316809-84-4P
316809-85-5P 316809-86-6P 316809-87-7P
316809-88-8P 316809-89-9P 316809-90-2P
316809-91-3P 316809-92-4P 316809-93-5P
316809-94-6P 316809-95-7P 316809-97-9P
316809-98-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azolylbenzamides and analogs for treating osteoporosis)
RN 316809-76-4 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-77-5 CAPLUS
CN Benzamide, 4-(5-chloro-1H-benzimidazol-2-yl)-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

546/199
514/322



RN 316809-78-6 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-hydroxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-79-7 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-80-0 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1-methyl-1H-benzimidazol-2-yl)-3-methoxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-81-1 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-82-2 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



548/295
514/252.19

RN 316809-83-3 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-hydroxy-N-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 316809-84-4 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



548|310.1
514/594

RN 316809-85-5 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-86-6 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methoxy-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-87-7 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-88-8 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-89-9 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



546/273.4
514/338.

RN 316809-90-2 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 316809-91-3 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 316809-92-4 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-2,5-dimethoxy-N-(1,2,2,6,6-pentamethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-93-5 CAPLUS

CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-2,5-dimethoxy-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-94-6 CAPLUS
CN Benzamide, 4-(5-chloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 316809-95-7 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)



RN 316809-97-9 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-(1-methylethoxy)-N-(2,2,6,6-tetramethyl-4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 316809-96-8
CMF C26 H32 Cl2 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 316809-98-0 CAPLUS
CN Benzamide, 4-(5,6-dichloro-1H-benzimidazol-2-yl)-3-ethoxy-N-[1-[[4-(3-iodobenzoyl)phenyl]methyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB 2-(2-Benzimidazolyl)benzoylhydrazineon condensation with different arom. aldehydes furnished Schiff's bases which on treatment with chloroacetyl chloride in the presence of triethylamine as basic catalyst afforded 2-azetidinones. The synthesized compds. have been tested in vitro for their antitubercular activity against Mycobacterium tuberculosis H37Rv. Some of these compds. exhibited highest antitubercular activity (>90% inhibition).

ACCESSION NUMBER: 2000:784863 CAPLUS
DOCUMENT NUMBER: 134:207752
TITLE: Synthesis of some 2-azetidinones as potential antitubercular agents
AUTHOR(S): Kagthara, Preeti; Upadhyay, Tejas; Doshi, Rajeev; Parekh, H. H.
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Indian Journal of Heterocyclic Chemistry (2000), 10(1), 9-12
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Prof. R. S. Varma
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:207752

IT **328407-64-3P 328407-65-4P 328407-66-5P**
328407-67-6P 328407-69-8P 328407-70-1P
328407-71-2P 328407-72-3P 328407-73-4P
328407-75-6P 328407-76-7P 328407-77-8P
328407-78-9P 328407-79-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. aldehyde benzimidazolylbenzoylhydrazones and benzimidazolylbenzoylaminoazetidinones as antitubercular agents)

RN 328407-64-3 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 328407-65-4 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(2-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-66-5 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(4-chlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-67-6 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(2,4-dichlorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-69-8 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [[4-(dimethylamino)phenyl]methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-70-1 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, (2-furanylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 328407-71-2 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(2-hydroxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-72-3 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(4-hydroxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-73-4 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(4-hydroxy-3-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-75-6 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(4-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-76-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(2-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-77-8 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(3-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-78-9 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, (3-phenyl-2-propenylidene)hydrazide (9CI) (CA INDEX NAME)



RN 328407-79-0 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(3,4,5-trimethoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



IT **328407-80-3P 328407-81-4P 328407-82-5P**
328407-83-6P 328407-85-8P 328407-86-9P
328407-91-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of arom. aldehyde benzimidazolylbenzoylhydrazones and benzimidazolylbenzoylaminoazetidinones as antitubercular agents)
RN 328407-80-3 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-(3-chloro-2-oxo-4-phenyl-1-azetidinyl)- (9CI) (CA INDEX NAME)



RN 328407-81-4 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(2-chlorophenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-82-5 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(4-chlorophenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-83-6 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(2,4-dichlorophenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-85-8 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-[4-(dimethylamino)phenyl]-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-86-9 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(2-furanyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-91-6 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(4-methoxyphenyl)-4-oxo-

1-azetidinyl]- (9CI) (CA INDEX NAME)



IT **148438-23-7P 328407-68-7P 328407-74-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. aldehyde benzimidazolylbenzoylhydrazones and benzimidazolylbenzoylaminoazetidinones as antitubercular agents)
RN 148438-23-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



RN 328407-68-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(3,4-dimethoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 328407-74-5 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, [(3-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



IT **328407-84-7P 328407-87-0P 328407-88-1P**
328407-89-2P 328407-90-5P 328407-92-7P
328407-93-8P 328407-94-9P 328407-95-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. aldehyde benzimidazolylbenzoylhydrazones and benzimidazolylbenzoylaminoazetidinones as antitubercular agents)
RN 328407-84-7 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(3,4-dimethoxyphenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-87-0 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(2-hydroxyphenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-88-1 CAPLUS

CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(4-hydroxyphenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-89-2 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(4-hydroxy-3-methoxyphenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-90-5 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(3-methoxyphenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-92-7 CAPLUS

CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(2-nitrophenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-93-8 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-(3-nitrophenyl)-4-oxo-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-94-9 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-oxo-4-(2-phenylethenyl)-1-azetidinyl]- (9CI) (CA INDEX NAME)



RN 328407-95-0 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[3-chloro-2-oxo-4-(3,4,5-trimethoxyphenyl)-1-azetidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Title compds. [I; R1 = H, alkyl; R2 = alkyl, chcloalkyl, aryl, pyridyl; R3 = H, alkyl, cycloalkyl; R4 = N, alkyl, alkoxy, (CH2)nA, (CH2)nYA; n = 1-5; A = alkyl, alkoxy; Y = O, s] and pharmaceutical acceptable salts are prepd. and tested as antiinflammatory agents having IL- 1, IL- 5, IL-6 inhibition effects and are useful as antiallergy agents in the treatment of chronic rheumatism in autoimmune diseases, osteoporosis in bone diseases. Thus, the title compd. II was prepd.

ACCESSION NUMBER: 2000:59980 CAPLUS
DOCUMENT NUMBER: 132:122619
TITLE: Preparation of 2,5,6-substituted benzimidazole derivatives
INVENTOR(S): Saito, Shuji; Matsumoto, Taro; Nakamura, Toshio
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000026430	A2	20000125	JP 1998-202744	19980702

PRIORITY APPLN. INFO.: JP 1998-202744 19980702
OTHER SOURCE(S): MARPAT 132:122619
IT **255917-73-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted benzimidazole derivs.)
RN 255917-73-8 CAPLUS
CN Benzamide, 4-[5-(cyclohexyloxy)-6-(4-pyridinylsulfinyl)-1H-benzimidazol-2-yl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



IT **255917-74-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted benzimidazole derivs.)
RN 255917-74-9 CAPLUS
CN Benzamide, 4-[5-(cyclohexyloxy)-6-(4-pyridinylsulfinyl)-1H-benzimidazol-2-yl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB 2-(Benzimidazol-2-yl)benzoyl hydrazide (1) when condensed with arom. acids in the presence of POCl3 afforded 2-aryl-5-[2-(benzimidazol-2-yl)phenyl]-1,3,4-oxadiazoles. The acid hydrazide 1 on cyclization with CNBr yield 2-amino-5-[2-(benzimidazol-2-yl)phenyl]-1,3,4-oxadiazole which on reaction with aryl sulfonyl chlorides and substituted benzoyl chloride give the corresponding sulfonamides and amides, resp. All the products were evaluated in vitro for their antimicrobial activity against several microbes and antitubercular activity against Mycobacterium tuberculosis H37Rv.

ACCESSION NUMBER: 1999:533594 CAPLUS
DOCUMENT NUMBER: 131:322584
TITLE: Synthesis of 2, 5-disubstituted 1,3,4-oxadiazoles as biologically active heterocycles
AUTHOR(S): Kagthara, Preeti R.; Shah, Niraj S.; Doshi, Rajeev K.; Parekh, H. H.
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(5), 572-576
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **148438-23-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and antimicrobial activity of oxadiazoles)

RN 148438-23-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB Substituted chalcones, prepd. by the treatment of 4-(5-benzoylbenzimidazol-2-yl-o-benzamido)acetophenone with araldehydes, on cyclization with hydroxylamine hydrochloride in EtOH furnish isoxazoles. The same chalcones on condensation with malononitrile yield cyanopyridines. Most of the compds. exhibit significant activity against Mycobacterium tuberculosis H37 Rv and MIC values are reported.

ACCESSION NUMBER: 1999:467099 CAPLUS
DOCUMENT NUMBER: 131:243208
TITLE: Synthesis and biological evaluation of some novel isoxazoles and cyanopyridines, a new class of potential anti-tubercular agents
AUTHOR(S): Doshi, Rajeev; Kagthara, Preeti; Parekh, Hansa
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(3), 348-352
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **244302-14-5P 244302-15-6P 244302-17-8P**
244302-19-0P 244302-20-3P 244302-21-4P
244302-22-5P 244302-24-7P 244302-25-8P
244302-26-9P 244302-27-0P 244302-28-1P
244302-29-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and antitubercular activity of isoxazoles and cyanopyridines)

RN 244302-14-5 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-(1-oxo-3-phenyl-2-propenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 244302-15-6 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(2-chlorophenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-17-8 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(4-chlorophenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-19-0 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(2,4-dichlorophenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-20-3 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(3,4-

dimethoxyphenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-21-4 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-22-5 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(2-furanyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-24-7 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(4-methoxyphenyl)-1-

oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-25-8 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-26-9 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(2-nitrophenyl)-1-oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-27-0 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[3-(3-nitrophenyl)-1-

oxo-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-28-1 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-(1-oxo-5-phenyl-2,4-pentadienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 244302-29-2 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]phenyl]- (9CI) (CA INDEX NAME)



IT **244302-30-5P 244302-31-6P 244302-32-7P**
244302-33-8P 244302-34-9P 244302-35-0P

244302-36-1P 244302-37-2P 244302-38-3P
244302-39-4P 244302-40-7P 244302-41-8P
244302-42-9P 244302-43-0P 244302-44-1P
244302-45-2P 244302-47-4P 244302-48-5P
244302-49-6P 244302-50-9P 244302-51-0P
244302-52-1P 244302-53-2P 244302-54-3P
244302-55-4P 244302-56-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antitubercular activity of isoxazoles and cyanopyridines)

RN 244302-30-5 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-(5-phenyl-3-isoxazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 244302-31-6 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(2-chlorophenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-32-7 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-33-8 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(2,4-dichlorophenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-34-9 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(3,4-dimethoxyphenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-35-0 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-[4-(dimethylamino)phenyl]-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-36-1 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(2-furanyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-37-2 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(4-methoxyphenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-38-3 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(4-hydroxy-3-methoxyphenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-39-4 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(2-nitrophenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-40-7 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(3-nitrophenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-41-8 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(2-phenylethenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-42-9 CAPLUS
CN Benzamide, 2-(5-benzoyl-1H-benzimidazol-2-yl)-N-[4-[5-(3,4,5-trimethoxyphenyl)-3-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 244302-43-0 CAPLUS
CN Benzamide, N-[4-(6-amino-5-cyano-4-phenyl-2-pyridinyl)phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-44-1 CAPLUS
CN Benzamide, N-[4-[6-amino-4-(2-chlorophenyl)-5-cyano-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-45-2 CAPLUS
CN Benzamide, N-[4-[6-amino-4-(4-chlorophenyl)-5-cyano-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-47-4 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(2,4-dichlorophenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-48-5 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(3,4-dimethoxyphenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-49-6 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-[4-(dimethylamino)phenyl]-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-50-9 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(2-furanyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-51-0 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(4-methoxyphenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-52-1 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(4-hydroxy-3-methoxyphenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-53-2 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(2-nitrophenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-54-3 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(3-nitrophenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-55-4 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(2-phenylethenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 244302-56-5 CAPLUS
CN Benzamide, N-[4-[6-amino-5-cyano-4-(3,4,5-trimethoxyphenyl)-2-pyridinyl]phenyl]-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



IT **244302-57-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and antitubercular activity of isoxazoles and cyanopyridines)
RN 244302-57-6 CAPLUS
CN Benzamide, N-(4-acetylphenyl)-2-(5-benzoyl-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB New arylamides, sulfonamides, and 5-oxoimidazolines have been synthesized by condensation of the acid hydrazide I with arom. acid chlorides, arylsulfonyl chlorides, and azlactones in dry pyridine. All the products were evaluated in vitro for their antimicrobial activity against several microbes and antitubercular activity against Mycobacterium tuberculosis H37Rv.

ACCESSION NUMBER: 1999:108437 CAPLUS
DOCUMENT NUMBER: 130:252290
TITLE: Synthesis of some arylamides, sulfonamides and 5-oxoimidazolines as novel bioactive compounds derived from benzimidazole
AUTHOR(S): Kagthara, Preeti R.; Shah, Niraj S.; Doshi, Rajeev K.; Parekh, H. H.
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Heterocyclic Communications (1998), 4(6), 561-566
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund Publishing House Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **221466-81-5P 221466-83-7P 221466-85-9P**
221466-86-0P 221466-88-2P 221466-90-6P
221466-92-8P 221466-94-0P 221466-95-1P
221466-96-2P 221466-97-3P 221466-99-5P
221467-00-1P 221467-01-2P 221467-03-4P
221467-04-5P 221467-05-6P 221467-06-7P
221467-07-8P 221467-08-9P 221467-09-0P
221467-10-3P 221467-11-4P 221467-12-5P
221467-13-6P 221467-14-7P 221467-15-8P
221467-16-9P 221467-17-0P 221467-18-1P
221467-19-2P 221467-20-5P 221467-21-6P
221467-22-7P 221467-23-8P 221467-24-9P
221467-26-1P 221467-29-4P 221467-32-9P
221467-36-3P 221467-41-0P 221467-45-4P
221467-48-7P 221467-52-3P 221467-55-6P
221467-58-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of arylamides, sulfonamides, and oxoimidazolines as bactericides, fungicides, and antitubercular agents)

RN 221466-81-5 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-benzoylhydrazide (9CI) (CA INDEX NAME)



RN 221466-83-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(4-bromobenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-85-9 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(2-chlorobenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-86-0 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(4-chlorobenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-88-2 CAPLUS

CN Benzoic acid, 3,4-dimethoxy-, 2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazide (9CI) (CA INDEX NAME)



RN 221466-90-6 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(2-hydroxybenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-92-8 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(2-methoxybenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-94-0 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(4-methoxybenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-95-1 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(2-methylbenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-96-2 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(3-methylbenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-97-3 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(4-methylbenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221466-99-5 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(2-nitrobenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221467-00-1 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(3-nitrobenzoyl)hydrazide (9CI) (CA INDEX NAME)



RN 221467-01-2 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(1-oxo-3-phenyl-2-propenyl)hydrazide (9CI) (CA INDEX NAME)



RN 221467-03-4 CAPLUS
CN Benzoic acid, 3,4,5-trimethoxy-, 2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-04-5 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)



RN 221467-05-6 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[[4-(acetylamino)phenyl]sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-06-7 CAPLUS
CN Benzoic acid, 2-(acetylamino)-5-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 221467-07-8 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(4-bromophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-08-9 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(3-carboxyphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-09-0 CAPLUS
CN Benzoic acid, 5-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 221467-10-3 CAPLUS
CN Benzoic acid, 5-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 221467-11-4 CAPLUS
CN Benzoic acid, 3-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 221467-12-5 CAPLUS
CN Benzoic acid, 5-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 221467-13-6 CAPLUS
CN Benzoic acid, 3-[[2-[2-(1H-benzimidazol-2-yl)benzoyl]hydrazino]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 221467-14-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(2-chlorophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-15-8 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(4-chlorophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-16-9 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(2,5-dibromophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-17-0 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(2,5-dichlorophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-18-1 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[(4-methylphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-19-2 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, 2-[[3-(2-carboxyethenyl)phenyl]sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 221467-20-5 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-5-oxo-2-phenyl-4-(phenylmethylene)-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-21-6 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4-[(2-chlorophenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-22-7 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4-[(4-chlorophenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-23-8 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4-[(3,4-dimethoxyphenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-24-9 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4-[[4-(dimethylamino)phenyl]methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-26-1 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4-(2-furanylmethylene)-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-29-4 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(2-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-32-9 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-36-3 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(4-hydroxy-3-methoxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-41-0 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(2-methoxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-45-4 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(4-methoxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-48-7 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(2-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-52-3 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-55-6 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-5-oxo-2-phenyl-4-(3-phenyl-2-propenylidene)-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 221467-58-9 CAPLUS
CN Benzamide, 2-(1H-benzimidazol-2-yl)-N-[4,5-dihydro-5-oxo-2-phenyl-4-[(3,4,5-trimethoxyphenyl)methylene]-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)



IT **148438-23-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylamides, sulfonamides, and oxoimidazolines as bactericides, fungicides, and antitubercular agents)
RN 148438-23-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title reagent reacts selectively with aliph. and arom. aldehydes in the presence of sulfuric acid to form highly fluorescent derivs. which are used for the HPLC detn. of the aldehydes with laser-induced fluorescence detection.

ACCESSION NUMBER: 1997:390891 CAPLUS
DOCUMENT NUMBER: 127:144546
TITLE: 4-(1-Methyl-2-phenanthro[9,10-d]imidazol-2-yl)-benzohydrazide as a derivatization reagent for aldehydes in high-performance liquid chromatography with conventional and laser-induced fluorescence detection
AUTHOR(S): Iwata, Tetsuharu; Ishimaru, Takayuki; Yamaguchi, Masatoshi
CORPORATE SOURCE: Fac. Pharmaceutical Sci., Fukuoka Univ., Fukuoka, 814-80, Japan
SOURCE: Analytical Sciences (1997), 13(3), 501-504
CODEN: ANSCEN; ISSN: 0910-6340
PUBLISHER: Japan Society for Analytical Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **160768-24-1**
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(4-(1-Methyl-2-phenanthro[9,10-d]imidazol-2-yl)-benzohydrazide as a derivatization reagent for aldehydes in high-performance liq. chromatog. with conventional and laser-induced fluorescence detection)

RN 160768-24-1 CAPLUS
CN Benzoic acid, 4-(1-methyl-1H-phenanthro[9,10-d]imidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II



III

AB 1,3,4-Oxadiazoles I (R = Ph, substituted Ph, CH:CHPh) have been synthesized by the cyclocondensation of acid hydrazide of 5-nitro-o-benzoylene-2,1-benzimidazole with different arom. acids in presence of POCl3, the same acid hydrazide was made to react with different azlactones II in dry pyridine which yielded 5-oxo-imidazolines III . All the products were screened for their antimicrobial activity against several microbes and antitubercular activity against Mycobacterium tuberculosis H37 Rv.

ACCESSION NUMBER: 1997:352800 CAPLUS
DOCUMENT NUMBER: 127:81401
TITLE: Synthesis of some novel 1,3,4-oxadiazoles and 5-oxo-imidazolines as potent biologically active agents
AUTHOR(S): Joshi, Dharti G.; Oza, Haresh B.; Parekh, H. H.
CORPORATE SOURCE: Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
SOURCE: Heterocyclic Communications (1997), 3(2), 169-174
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **191804-66-7P 191804-73-6P 191804-74-7P 191804-75-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn., bactericidal, fungicidal, and tuberculostatic activity of (benzimidazolylphenyl)oxadiazoles and (benzimidazolylbenzamido)imidazol

ones)

RN 191804-66-7 CAPLUS

CN Benzamide, N-[4-[(4-chlorophenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-73-6 CAPLUS

CN Benzamide, N-[4,5-dihydro-4-[(2-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-74-7 CAPLUS

CN Benzamide, N-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-75-8 CAPLUS

CN Benzamide, N-[4,5-dihydro-4-[(4-methoxyphenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



IT **191804-48-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., bactericidal, fungicidal, and tuberculostatic activity of (benzimidazolylphenyl)oxadiazoles and (benzimidazolylbenzamido)imidazolones)
RN 191804-48-5 CAPLUS
CN Benzoic acid, 2-(5-nitro-1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



IT **191804-64-5P 191804-65-6P 191804-68-9P**
191804-70-3P 191804-72-5P 191804-76-9P
191804-77-0P 191804-78-1P 191804-80-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., bactericidal, fungicidal, and tuberculostatic activity of (benzimidazolylphenyl)oxadiazoles and (benzimidazolylbenzamido)imidazolones)
RN 191804-64-5 CAPLUS
CN Benzamide, N-[4,5-dihydro-5-oxo-2-phenyl-4-(phenylmethylene)-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-65-6 CAPLUS

CN Benzamide, N-[4-[(2-chlorophenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-68-9 CAPLUS
CN Benzamide, N-[4-[(3,4-dimethoxyphenyl)methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-70-3 CAPLUS
CN Benzamide, N-[4-[[4-(dimethylamino)phenyl]methylene]-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-72-5 CAPLUS
CN Benzamide, N-[4-(2-furanylmethylene)-4,5-dihydro-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-76-9 CAPLUS
CN Benzamide, N-[4,5-dihydro-4-[(2-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-77-0 CAPLUS
CN Benzamide, N-[4,5-dihydro-4-[(3-nitrophenyl)methylene]-5-oxo-2-phenyl-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-78-1 CAPLUS
CN Benzamide, N-[4,5-dihydro-5-oxo-2-phenyl-4-(3-phenyl-2-propenylidene)-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 191804-80-5 CAPLUS
CN Benzamide, N-[4,5-dihydro-5-oxo-2-phenyl-4-[(3,4,5-trimethoxyphenyl)methylene]-1H-imidazol-1-yl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II



AB The synthesis of 14 monocationic and six dicationic analogs of Hoechst 33258 is described. Seven monocationic benzimidazoles I [R1 = Q1, Q2, Q3; R2 = OH, OMe, OEt] and 3 dicationic benzimidazoles I [R1 = R2 = Q1, Q2, Q3] are obtained in 5 steps starting from 4-acetamidobenzonitrile. Seven monocationic bisbenzimidazoles II [R1 = Q1, Q2, Q3; R2 = OH, OMe, OEt] are synthesized in 4 steps starting from 4-amino-3-nitrobenzonitrile (III). The dicationic bisbenzimidazoles II [R1 = R2 = Q1, Q2, Q3] are obtained in 6 steps starting from III.

ACCESSION NUMBER: 1996:582799 CAPLUS
DOCUMENT NUMBER: 125:328595
TITLE: Synthesis of mono-cationic and dicationic analogs of Hoechst 33258
AUTHOR(S): Czarny, Agnieszka; Wilson, W. D.; Boykin, David W.
CORPORATE SOURCE: Dep. Chem. Cent. Biotechnol. Drug Design, Georgia State Univ., Atlanta, GA, 30303-3083, USA
SOURCE: Journal of Heterocyclic Chemistry (1996), 33(4), 1393-1397
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **183296-08-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of mono- and dicationic benzimidazoles and bisbenzimidazoles as analogs of Hoechst 33258)

RN 183296-08-4 CAPLUS
CN 1H-Benzimidazole-5-carboximidic acid, 2-[4-[imino(2-

methoxyethoxy)methyl]phenyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I II

AB Title compds. (I; R = heterocyclyl, heteroaryl; R1 = fluoromethyl, halo, alkyl, alkoxy, etc.; R2,R3 = H, halo, alkyl, alkoxy, etc) were prepd. as hydrogen ion-sodium antiporter inhibitors (no data). Thus, 2-methyl-4-chloro-5-methylsulfonylbenzoic acid was aminated by imidazole and the Me ester amidated by guanidine to give title compd. II.

ACCESSION NUMBER: 1996:303752 CAPLUS
DOCUMENT NUMBER: 124:343303
TITLE: Preparation of N-(heterocyclylbenzoyl)guanidines as hydrogen ion-sodium antiporter inhibitors
INVENTOR(S): Gericke, Rolf; Dorsch, Dieter; Baumgarth, Manfred; Minck, Klaus-Otto; Beier, Norbert
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 699666	A1	19960306	EP 1995-113307	19950824
EP 699666	B1	19990107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4430861	A1	19960307	DE 1994-4430861	19940831
SK 281446	B6	20010312	SK 1995-1029	19950821
AU 9530250	A1	19960314	AU 1995-30250	19950824
AU 702258	B2	19990218		
AT 175406	E	19990115	AT 1995-113307	19950824
ES 2129716	T3	19990616	ES 1995-113307	19950824
CA 2157146	AA	19960301	CA 1995-2157146	19950829
CZ 286400	B6	20000412	CZ 1995-2202	19950829
NO 9503404	A	19960301	NO 1995-3404	19950830
ZA 9507284	A	19960402	ZA 1995-7284	19950830
HU 73183	A2	19960628	HU 1995-2548	19950830
CN 1126720	A	19960717	CN 1995-116901	19950830
CN 1058004	B	20001101		
US 5753680	A	19980519	US 1995-520780	19950830
RU 2152390	C1	20000710	RU 1995-114847	19950830
PL 183393	B1	20020628	PL 1995-310224	19950830
JP 08073427	A2	19960319	JP 1995-245151	19950831
BR 9503881	A	19960917	BR 1995-3881	19950831

PRIORITY APPLN. INFO.: DE 1994-4430861 A 19940831
OTHER SOURCE(S): MARPAT 124:343303
IT **176644-25-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(heterocyclylbenzoyl)guanidines as hydrogen ion-sodium antiporter inhibitors)

RN 176644-25-0 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-4-(1H-benzimidazol-2-yl)-2-methyl-5-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I





II

AB Benzimidazoles and imidazopyridines I [R = Q1, or Q2, where R1 = aryl or heteroaryl; R2 = H or C1-6 alkyl; X = Y(CH2)n, CONH(CH2)p, NHCO(CH2)p, C3-6 alkylene, alkenylene, alkynylene; Y = O, S, or NH; n = 2-5; p = 1-4; Z = N or CH] and their isomers and acid addn. salts are described. I are useful as CNS agents, particularly antipsychotic agents, and for the treatment of other disorders which respond to dopaminergic blockade, including psychotic depression, substance abuse, and compulsive disorders. For example, cyclization of 1,2-diaminobenzene with 4-[3-(4-phenylpiperazin-1-yl)propoxy]benzaldehyde in nitrobenzene [oxidizing solvent] at 160.degree. gave title benzimidazole deriv. II. Assays for inhibition of [3H]-spiperone binding to human D3 and D2 receptors by II gave IC50 values of 1.0 and 406 nM, resp., showing selectivity for D3 receptor. II also had ED50 of 2.3 mg/kg i.p. for inhibiting locomotor activity in rats.

ACCESSION NUMBER: 1996:150249 CAPLUS
DOCUMENT NUMBER: 124:202263
TITLE: Benzimidazole and imidazopyridine derivatives, their preparation, and their use as dopaminergic agents selective for the dopamine D3 receptor
INVENTOR(S): Downing, Dennis Michael; Glase, Shelly Ann; Johnson, Stephen Joseph; Wise, Lawrence David; Wright, Jonathan Leonard
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9530659	A1	19951116	WO 1995-US3816	19950327

W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5486517	A	19960123	US 1994-240355	19940510
AU 9521978	A1	19951129	AU 1995-21978	19950327
ZA 9503752	A	19960111	ZA 1995-3752	19950509
PRIORITY APPLN. INFO.:			US 1994-240355	19940510
			WO 1995-US3816	19950327

OTHER SOURCE(S): MARPAT 124:202263

IT **174266-39-8P 174266-40-1P 174266-41-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazole and imidazopyridine derivs. as D3-selective dopaminergic antagonists)

RN 174266-39-8 CAPLUS
CN Benzamide, 4-(1H-benzimidazol-2-yl)-N-[2-(4-phenyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 174266-40-1 CAPLUS
CN Benzamide, 4-(1H-benzimidazol-2-yl)-N-[2-[4-[2-(propylthio)phenyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 174266-41-2 CAPLUS
CN Benzamide, 4-(1H-benzimidazol-2-yl)-N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Dimeric benzimidazoles I [wherein R is NR1R2 wherein R1 and R2 are each the same or different and each is alkyl of from 1 to 6 carbon atoms, alkenyl of from 2 to 6 carbon atoms, alkynyl of from 2 to 6 carbon atoms, arylalkyl wherein alkyl is from 1 to 6 carbon atoms, 2-thienylalkyl wherein alkyl is from 1 to 6 carbon atoms or R1 and R2 together with the nitrogen which they substitute form a 1-piperidinyl, or 1-pyrrolidinyl ring or R is II; X is alkyl of from 2 to 6 carbon atoms, alkenyl of from 2 to 6 carbon atoms, or alkynyl of from 2 to 6 carbon atoms; Y is O(CH2)n wherein n is an integer of from 2 to 6, or CONH(CH2)p wherein p is zero or an integer of from 1 to 6; and Z is hydrogen, hydroxyl, alkyl of from 1 to 6 carbon atoms, alkoxy of from 1 to 6 carbon atoms, or Y--R wherein Y and R are as defined above; and corresponding isomers thereof; or a pharmaceutically acceptable acid addn. salt thereof] are described, as well as methods for the prepn. and pharmaceutical compn. of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders. Thus, e.g., alkenylation of 2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1H-benzimidazole (prepn. given) with trans-1,4-dichloro-2-butene afforded (E)-1,1'-(2-butene-1,4-diyl)bis[2-[4-[3-(1-pyrrolidinyl)propoxy]phenyl]-1H-benzimidazole] which inhibited [3H]spiperone binding to human D3 receptors with IC50 = 9 nM vs. 56 nM for human D2 receptors.

ACCESSION NUMBER: 1995:602401 CAPLUS
DOCUMENT NUMBER: 123:55882
TITLE: Dimeric benzimidazoles as selective dopamine D3 receptor antagonists
INVENTOR(S): Downing, Dennis M.; Wise, Lawrence D.; Wright, Jonathan L.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5414010	A	19950509	US 1994-240354	19940510

WO 9530658 A1 19951116 WO 1995-US3814 19950327
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9521976 A1 19951129 AU 1995-21976 19950327
ZA 9503751 A 19960111 ZA 1995-3751 19950509
PRIORITY APPLN. INFO.: US 1994-240354 19940510
WO 1995-US3814 19950327
OTHER SOURCE(S): MARPAT 123:55882
IT **164917-33-3P 164917-34-4P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(dimeric benzimidazoles as selective dopamine D3 receptor antagonists)
RN 164917-33-3 CAPLUS
CN Benzamide, 4,4'-[1,4-butanediylbis(1H-benzimidazole-1,2-diyl)]bis[N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 164917-34-4 CAPLUS
CN Benzamide, 4,4'-[1,4-butanediylbis(1H-benzimidazole-1,2-diyl)]bis[N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



AB Title compds. [I; R = substituted Bz, (un)substituted carbamoyl, etc.; R1 = H, (hydroxy)alkyl; R2 = (un)substituted phenyl(oxy)alkyl; NR1R2 = (un)substituted pyrrolidino, -piperidino, morpholino, -1,2,3,4-tetrahydroisoquinolino] were prepd. Thus, title compd. II gave 24.0mL/min increase in femoral artery blood flow at 10-30.mu.L of a 100nM soln. intra-arterially in dogs.

ACCESSION NUMBER: 1995:511433 CAPLUS
DOCUMENT NUMBER: 123:198624
TITLE: Preparation of N-benzoylpiperidine-4-amines as peripheral vasodilators
INVENTOR(S): Fujioka, Takafumi; Teramoto, Shuji; Tanaka, Michinori; Shimizu, Hiroshi; Tabusa, Fujio; Tominaga, Michiaki
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 505 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422826	A1	19941013	WO 1994-JP549	19940404
W: AU, CA, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2136999	AA	19941013	CA 1994-2136999	19940404
AU 9462928	A1	19941024	AU 1994-62928	19940404
AU 674207	B2	19961212		
EP 650476	A1	19950503	EP 1994-910593	19940404
EP 650476	B1	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1104412	A	19950628	CN 1994-190181	19940404
CN 1052224	B	20000510		
AT 219766	E	20020715	AT 1994-910593	19940404
ES 2179071	T3	20030116	ES 1994-910593	19940404
JP 06340627	A2	19941213	JP 1994-95532	19940407
JP 2825755	B2	19981118		
US 5656642	A	19970812	US 1994-347454	19941206
US 5760058	A	19980602	US 1997-794322	19970203
HK 1003708	A1	20020927	HK 1998-102819	19980403
US 6136826	A	20001024	US 1998-66930	19980428

PRIORITY APPLN. INFO.: JP 1993-80712 A 19930407
WO 1994-JP549 W 19940404

US 1994-347454 A3 19941206
US 1997-794322 A3 19970203

OTHER SOURCE(S): MARPAT 123:198624

IT **167621-61-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzoylpiperidine-4-amines as peripheral vasodilators)

RN 167621-61-6 CAPLUS

CN 4-Piperidinamine, 1-[4-(1H-benzimidazol-2-yl)benzoyl]-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compds. of the formula I wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; RA is II. IC50 (nM) values were detd. for both [3H]oxytocin and [3H]vasopressin: 560-2500 and 39-320, resp. Pharmaceutical formulations were given.

ACCESSION NUMBER: 1995:227441 CAPLUS
DOCUMENT NUMBER: 122:105695
TITLE: Carbostyril oxytocin receptor antagonists
INVENTOR(S): Freidinger, Roger M.; Pawluczyk, Joseph M.; Pettibone, Douglas J.; Williams, Peter D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 177 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5356904	A	19941018	US 1992-957491	19921007
WO 9519773	A1	19950727	WO 1994-US847	19940119

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1992-957491 19921007
OTHER SOURCE(S): MARPAT 122:105695
IT **141134-70-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(carbostyril oxytocin receptor antagonists)
RN 141134-70-5 CAPLUS
CN Piperidine, 1-[4-(1H-benzimidazol-2-yl)benzoyl]-4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB 4-(1-Methylphenanthro[9,10-d]imidazol-2-yl)benzohydrazide was developed as a highly sensitive and selective fluorescence derivatization reagent for carboxylic acids in HPLC. The reaction conditions were optimized with C16-C20 linear satd. fatty acids. The derivatization reaction proceeded in aq. soln. in the presence of pyridine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at mild temps. The resulting fluorescent derivs. were sepd. by reversed-phase (C18) liq. chromatog. with aq. methanol and were detected with conventional fluorescence detection at 460 nm with excitation at 325 nm. The detection limits (signal-to-noise ratio = 3) for the acids are 2-12 fmol for an injection vol. of 10 .mu.L. The fluorescent derivs. display an excitation max. at 325 nm, which coincides closely with the light emission of the helium-cadmium laser. Hence, HPLC with the reagent was combined with helium-cadmium laser-induced fluorescence detection. Using this system, attomole detection limits (70-100 amol on-column) were achieved for various carboxylic acids.

ACCESSION NUMBER: 1995:71801 CAPLUS
DOCUMENT NUMBER: 122:122239
TITLE: 4-(1-Methylphenanthro[9,10-d]imidazol-2-yl)benzohydrazide as derivatization reagent for carboxylic acids in high-performance liquid chromatography with conventional and laser-induced fluorescence detection
AUTHOR(S): Iwata, Tetsuharu; Hirose, Tsuyoshi; Nakamura, Masaru; Yamaguchi, Masatoshi
CORPORATE SOURCE: Fac. Pharmaceutical Sciences, Fukuoka Univ., Fukuoka, 814-80, Japan
SOURCE: Analyst (Cambridge, United Kingdom) (1994), 119(8), 1747-51
CODEN: ANALAO; ISSN: 0003-2654
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **160768-24-1P**
RL: ARG (Analytical reagent use); PNU (Preparation, unclassified); ANST (Analytical study); PREP (Preparation); USES (Uses)
(prepn. and use of methylphenanthroimidazolylbenzohydrazide derivatization reagent for carboxylic acids in HPLC with conventional and laser-induced fluorescence detection)

RN 160768-24-1 CAPLUS
CN Benzoic acid, 4-(1-methyl-1H-phenanthro[9,10-d]imidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB A series of 2-arylimidazo[1,2-a]pyrazines I (X = SOMe, CONH2, O3SMe; R = H, OMe) has been prepd. and evaluated for inotropic activity. I (X = SOMe, R = OMe) (BW315C) displayed potent inotropic effects having comparable in vitro and and in vivo inotropic potencies to those of isomazole. Structure-activity relationships are discussed.

ACCESSION NUMBER: 1994:409327 CAPLUS
DOCUMENT NUMBER: 121:9327
TITLE: Synthesis and pharmacological properties of BW315C and other inotropic 2-arylimidazo[1,2-a]pyrazines
AUTHOR(S): Barraclough, Paul; Black, James W.; Cambridge, David; Gerskowitch, V. Paul; Giles, Heather; Glen, Robert C.; Hull, Robert A. D.; Iyer, Ramachandran; King, W. Richard; et al.
CORPORATE SOURCE: Dep. Med. Chem., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(4), 509-14
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:9327

IT **130179-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(inotropic activity of)

RN 130179-73-6 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB Title compds. I [R = (un)substituted Ph, etc.] were prepd. by hydrazinolysis of o-benzoyl-2,1-benzimidazole followed by cyclization with RCO2H. The bactericidal activity of I was screened.

ACCESSION NUMBER: 1993:449309 CAPLUS
DOCUMENT NUMBER: 119:49309
TITLE: 1,3,4-Oxadiazoles. Part XIV: 2-Aryl-5-(o-benzimidazol-2'-yl-phenyl)-1,3,4-oxadiazoles
AUTHOR(S): Bapodra, Atul; Joshi, Nailesh; Pandya, Ajay; Parekh, Hansa
CORPORATE SOURCE: Chem. Dep., Saurahtra Univ., Rajkot, 360 005, India
SOURCE: Journal of the Institution of Chemists (India) (1992), 64(2), 65-6
CODEN: JOICA7; ISSN: 0020-3254
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 119:49309

IT **148438-23-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of, with carboxylic acids)

RN 148438-23-7 CAPLUS
CN Benzoic acid, 2-(1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title compds. are prepd. by treating arom. diamines having 2 amino groups at adjacent carbons with nitrile compds. in the presence of Ru complexes. Treating o-phenylenediamine with PhCN in AcNMe2 in the presence of RuCl2(PPh3)3 at 160.degree. for 24 h gave 81% 2-phenylbenzimidazole.

ACCESSION NUMBER: 1993:80794 CAPLUS
DOCUMENT NUMBER: 118:80794
TITLE: Preparation of condensed aromatic imidazoles
INVENTOR(S): Yamashita, Mitsuhiro; Imai, Yoshio; Kakimoto, Masaaki
PATENT ASSIGNEE(S): Tokuyama Soda Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04279571	A2	19921005	JP 1991-103272	19910305

PRIORITY APPLN. INFO.: JP 1991-103272 19910305
OTHER SOURCE(S): CASREACT 118:80794

IT **145855-32-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 145855-32-9 CAPLUS
CN Benzamide, 4-(1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 33 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title reagent was prepd. and characterized by structural anal. for use as a derivatization reagent for detn. of carboxylic acids by high-performance liq. chromatog. using fluorometric detection. The reagent is useful for the highly sensitive (femtomole levels) HPLC detn. of linear satd. fatty acids.

ACCESSION NUMBER: 1993:72807 CAPLUS
DOCUMENT NUMBER: 118:72807
TITLE: 4-(5,6-Dimethoxy-2-benzimidazoyl)benzohydrazide as fluorescence derivatization reagent for carboxylic acids in high-performance liquid chromatography
AUTHOR(S): Iwata, Tetsuharu; Nakamura, Masaru; Yamaguchi, Masatoshi
CORPORATE SOURCE: Fac. Pharm. Sci., Fukuoka Univ., Fukuoka, 814-01, Japan
SOURCE: Analytical Sciences (1992), 8(6), 889-92
CODEN: ANSCEN; ISSN: 0910-6340
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **145697-65-0P**, 4-(5,6-Dimethoxy-2-benzimidazoyl)benzohydrazide
RL: SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(prepn. and use of, as derivatization reagent for detn. of carboxylic acids by high-performance liq. chromatog. using fluorometric detection)

RN 145697-65-0 CAPLUS

CN Benzoic acid, 4-(5,6-dimethoxy-1H-benzimidazol-2-yl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB A series of 2-arylimidazo[1,2-a]pyrimidines were prepd. and evaluated for inotropic activity. Thus, 2-aminopyrimidine was treated with 2,4-(MeO)2C6H3COCH2Br to give 52% I (R = MeO). Three of these heterocycles I (R = MeO, MeS, MeSO3) displayed more potent inotropic effects in vitro than isomazole. The in vivo inotropic potencies of I (R = MeSO3, NH2CO) were similar to those of isomazole and sulmazole resp. The effects of some 'A' and 'C' ring substituents on the inotropic activities of the imidazo[1,2-a]pyrimidines were different from those on the imidazopyridines. Nevertheless the inotropic potencies of several imidazo[1,2-a]pyrimidines were closed to those of their 1H-imidazo[4,5-b]pyridine isomers than to those of the corresponding isomazole analogs. Structure-activity relationships are discussed in detail.

ACCESSION NUMBER: 1992:571309 CAPLUS
DOCUMENT NUMBER: 117:171309
TITLE: Inotropic 2-arylimidazo[1,2-a]pyrimidines
AUTHOR(S): Barraclough, P.; Black, J. W.; Cambridge, D.; Capon, E.; Cox, M. R.; Firmin, D.; Gerskowitch, V. P.; Giles, H.; Glen, R. C.; et al.
CORPORATE SOURCE: Dep. Med. Chem., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK
SOURCE: European Journal of Medicinal Chemistry (1992), 27(3), 207-17
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **89469-25-0 130179-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(inotropic activity of)

RN 89469-25-0 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 130179-73-6 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)


O
C—NH2
H
N
N
N
OMe

L4 ANSWER 35 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

Q= 

Q1= 



II

AB Title compds. I [X = O,S; Y = H, C1-6 alkyl; R = Q, Q1; A = C1-6 alkenyl; R1 = (substituted) benzoyl; n = 1,2; R2 = substituted benzoyl; dotted line is optional double bond; with provisos] were prepd. as vasopressin antagonists. Thus, 1-(4-piperidinyl)-3,4-dihydrocarbostyril hydrochloride and Lawesson's Reagent were refluxed for 40 h in toluene to give 1-(4-piperidinyl)-3,4-dihydrothiocarbostyril. This was condensed with 4-ethoxy-2-methoxybenzoic acid in the presence of bis(2-oxooxazolidin-3-yl)phosphinyl chloride and Et3N to give title compd. II. II had IC50 of 0.73 .mu.M against [3H]-vasopressin binding to rat liver plasma membrane. Formulations contg. I were prepd.

ACCESSION NUMBER: 1992:214371 CAPLUS
DOCUMENT NUMBER: 116:214371
TITLE: Preparation of carbostyril derivatives as vasopressin antagonists
INVENTOR(S): Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Komatsu, Hajime; Tanaka, Michinori; Kitano, Kazuyoshi; Fujioka, Takafumi; et al.
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 470514	A1	19920212	EP 1991-112999	19910802
EP 470514	B1	19970219		
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2100187	T3	19970616	ES 1991-112999	19910802
AU 9181574	A1	19920305	AU 1991-81574	19910805
AU 638346	B2	19930624		
US 5300513	A	19940405	US 1991-740676	19910806
CN 1058779	A	19920219	CN 1991-105415	19910807
CN 1036651	B	19971210		
JP 05004984	A2	19930114	JP 1991-197607	19910807

JP 3165867 B2 20010514
PRIORITY APPLN. INFO.: JP 1990-210025 A 19900807
OTHER SOURCE(S): MARPAT 116:214371
IT **141134-70-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as vasopressin antagonist)
RN 141134-70-5 CAPLUS
CN Piperidine, 1-[4-(1H-benzimidazol-2-yl)benzoyl]-4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 36 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB Isomazole analogs, e.g., I, which have achiral electron withdrawing substituents at the 4'-position and analogs with heterocyclic 'C' rings were prepd. and evaluated as inotropic agents. Pyridyl could replace Ph in the 'C' ring without loss of activity. The 4'-methylsulfonyl, -cyano, -carboxamido, and acetyl analogs had similar inotropic potencies to Isomazole while displaying superior cardiovascular profiles in in vivo studies.

ACCESSION NUMBER: 1990:591241 CAPLUS
DOCUMENT NUMBER: 113:191241
TITLE: Cardiotonic C ring modified isomazole analogs
AUTHOR(S): Barraclough, Paul; Black, James W.; Cambridge, David; Demaine, Derek A.; Gerskowitch, V. Paul; Giles, Heather; Hill, Alan P.; Hull, Robert A. D.; Lyer, Ramachandran; et al.
CORPORATE SOURCE: Dep. Med. Chem., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1990), 323(8), 507-12
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **130179-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(inotropic activity of)
RN 130179-73-6 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)



IT **130179-79-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 130179-79-2 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 37 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I

AB A series of 2-substituted 1H-imidazo[4,5-b]pyridines, e.g., I, and the isomeric 1H-imidazo[4,5-c]pyridine derivs. was prepd. by, e.g., condensing 2,3-diaminopyridine with 2,4-(MeO)(NC)C6H3COCl, and evaluated as inotropic agents. The 1H-imidazo-[4,5-b] derivs. were consistently more potent than their isomers in the [4,5-c] series in isolated guinea pig papillary muscle prepns. Structure-activity relationships and the species-dependence of inotropic potencies are discussed.

ACCESSION NUMBER: 1990:591240 CAPLUS
DOCUMENT NUMBER: 113:191240
TITLE: Inotropic activities of imidazopyridines
AUTHOR(S): Barraclough, Paul; Black, James W.; Cambridge, David; Gerskowitch, V. Paul; Hull, Robert A. D.; Lyer, Ramachandran; King, W. Richard; Kneen, Clare O.; Nobbs, Malcolm S.; et al.
CORPORATE SOURCE: Dep. Med. Chem., Wellcome Res. Lab., Beckenham/Kent, BR3 3BS, UK
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1990), 323(8), 501-5
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **130179-73-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(inotropic activity of)
RN 130179-73-6 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)



IT **89469-25-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and inotropic activity of)
RN 89469-25-0 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX

NAME)



IT **89454-64-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 89454-64-8 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 38 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I II

AB The title compds. [I; R = QZ; Q = R3-R5-substituted phenyl; R1 = H, alkyl, alkenyl, cycloalkyl; R2 = H, cyano, alkyl, alkenyl, (un)substituted CO2H; R1R2 = alkylidene, cycloalkylidene; R3-R5 = H, OH, alkoxy, alkylthio, halo, NO2, cyano, etc.; X = O, S; Z = bond, alkylene, vinylene] were prepd., e.g., by condensation of indolinone II (R6 = R7 = NH2) with QZCOCl. II (R1 = R2 = Me, R6 = NO2, R7 = NH2) was stirred with BzCl and the product hydrogenated over Pd/C to give 81% I (R = Ph, R1 = R2 = Me, X = O). Similarly prepd. I [R = 2,4-(MeO)2C6H3, R1 = R2 = Me, X = O] gave an increase of rat heart contractility of 4.2 mmHg/s at 10 mg/kg i.v.

ACCESSION NUMBER: 1989:515180 CAPLUS
DOCUMENT NUMBER: 111:115180
TITLE: Preparation of 6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones as cardiovascular agents
INVENTOR(S): Mertens, Alfred; Hoelck, Jens Peter; Kampe, Wolfgang; Mueller-Beckmann, Bernd; Strein, Klaus; Schaumann, Wolfgang
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
SOURCE: U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 807,260. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4810801	A	19890307	US 1987-103895	19871001
DE 3445669	A1	19860619	DE 1984-3445669	19841214
US 4710510	A	19871201	US 1985-807260	19851210

PRIORITY APPLN. INFO.: DE 1984-3445669 19841214
US 1985-807260 19851210
OTHER SOURCE(S): CASREACT 111:115180; MARPAT 111:115180
IT **122455-08-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as cardiovascular agent)
RN 122455-08-7 CAPLUS
CN Benzamide, 3-methoxy-4-(1,5,6,7-tetrahydro-7,7-dimethyl-6-oxopyrrolo[2,3-f]benzimidazol-2-yl)- (9CI) (CA INDEX NAME)


O
C—NH2
Me
Me
H
N
O
HN
N
OMe

L4 ANSWER 39 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II



III



IV

AB The 1,2-dimethyl-1,2,4-benzotriazines I (R1 = H, R2 = Ph; R1 = CF3, R2 = Me, Ph) were prepd. by acid-catalyzed cyclization of the 2-aminophenylhydrazine derivs. Compds. I (R1 = H, CF3 R2 = Ph) undergo a thermal elimination to fully arom. benzotriazines. However, the 2-acyl deriv. II rearranges to the thermodynamically more stable 4-acyl compd. In the presence of traces of water, a ring contraction to benzimidazoles is a competing reaction. For II the nitrogen fragment is retained in the benzamide III. A mechanism for the ring contraction was suggested in which initial hydration of the imine bond gives 1,2,3,4-tetrahydrobenzotriazines which then recyclize to benzimidazoles. The benzimidazo[2,1-a]phthalazine IV was shown not to be an intermediate in the water-mediated ring contraction of II.

ACCESSION NUMBER: 1989:407347 CAPLUS
DOCUMENT NUMBER: 111:7347
TITLE: Synthesis and thermal reactions of 1,2-dihydro-1,2,4-benzotriazines
AUTHOR(S): King, Frank D.
CORPORATE SOURCE: Res. Div., Beecham Pharm., Harlow/Essex, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1988), (12), 3381-5
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:7347

IT **120914-45-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 120914-45-6 CAPLUS
CN Benzamide, 2-[1-methyl-5-(trifluoromethyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)


Me
H2N
O
C
N
N
F3C

L4 ANSWER 40 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title sheets are prepd. by wet spinning together polymers with high rigidity and heat-bondable polymers to form fibrids and then hot pressing the fibrids. Thus, a mixt. of 20.0 parts poly(p-phenylenebenzobisthiazole) and 20.0 parts poly(m-phenyleneisophthalamide-terephthalamide) in 2600 parts methanesulonic acid was spun into a coagulating bath, shread in a mixer, and washed to give fibrids. A slurry contg. these fibrids was fed to a papermaking machine and pressed 15 h at 310.degree. to give a heat-resistant paper substitute with ratio of tensile strength in MPa to modulus in GPa 19:15.

ACCESSION NUMBER: 1987:198029 CAPLUS
DOCUMENT NUMBER: 106:198029
TITLE: Synthetic fibrids for heat-resistant high-modulus sheets
INVENTOR(S): Mera, Hiroshi; Nishihara, Toshio; Endo, Zenichiro
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62006958	A2	19870113	JP 1985-144577	19850703
US 4749753	A	19880607	US 1986-880828	19860701

PRIORITY APPLN. INFO.:
JP 1985-144576 19850703
JP 1985-144577 19850703
JP 1985-144578 19850703
JP 1985-163057 19850725

IT **26615-36-1**
RL: USES (Uses)
(fiber, biconstituent with polyazole fibers, fibrids, for heat-resistant paper substitutes)

RN 26615-36-1 CAPLUS

CN Poly[(1-phenyl-1H-benzimidazole-2,5-diyl)iminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)



L4 ANSWER 41 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title fibrids for manuf. of heat-resistant tough paper substitutes are prepd. by spinning or extruding liqs. contg. polymers with high rigidity and heat-bondable matrix polymers into a coagulating bath, drawing the fibers or films, and then pulverizing them. Thus, a mixt. of 20.0 parts poly(p-phenylenebenzothiazole) and 20.0 parts poly(m-phenyleneisophthalamide-terephthalamide) in 2600 parts methanesulfonic acid was spun into a coagulating bath, drawn 30% in H2O, washed, dried, drawn 10% at 450.degree., and fibrillated in a beater to give fibrids. A slurry contg. these fibrids was fed to a papermaking machine and pressed 15 h at 310.degree. to give a heat-resistant paper substitute with high bending strength.

ACCESSION NUMBER: 1987:198028 CAPLUS
DOCUMENT NUMBER: 106:198028
TITLE: Manufacture of heat-bondable synthetic fibrids
INVENTOR(S): Mera, Hiroshi; Nishihara, Toshio; Endo, Zenichiro
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62006916	A2	19870113	JP 1985-144578	19850703
US 4749753	A	19880607	US 1986-880828	19860701

PRIORITY APPLN. INFO.:
JP 1985-144576 19850703
JP 1985-144577 19850703
JP 1985-144578 19850703
JP 1985-163057 19850725

IT **26615-36-1**
RL: USES (Uses)
(fiber, biconstituent with polyazole fibers, fibrids for paper substitutes)

RN 26615-36-1 CAPLUS

CN Poly[(1-phenyl-1H-benzimidazole-2,5-diyl)iminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The title fibrids for heat-resistant paper substitutes are prepd. by wet spinning together polymers with high rigidity and heat-bondable polymers and then fibrillating the fibers by shearing. Thus, a mixt. of 20.0 g poly(p-phenylenebenzobisthiazole) and 20.0 g poly(m-phenyleneisophthalamide-terephthalamide) in 2.6 kg methanesulfonic acid was spun into a coagulating bath, sheared in a mixer, and washed to give fibrids. A slurry contg. these fibrids was fed to a papermaking machine and pressed 15 h at 310.degree. to give a heat-resistant paper substitute with ratio of tensile strength in MPa to modulus in GPa 35:15.

ACCESSION NUMBER: 1987:198027 CAPLUS
DOCUMENT NUMBER: 106:198027
TITLE: Heat-resistant heat-bondable synthetic fibrid manufacture
INVENTOR(S): Mera, Hiroshi; Nishihara, Toshio; Endo, Zenichiro
PATENT ASSIGNEE(S): Agency of Industrial Sciences and Technology, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62006915	A2	19870113	JP 1985-144576	19850703
US 4749753	A	19880607	US 1986-880828	19860701

PRIORITY APPLN. INFO.:
JP 1985-144576 19850703
JP 1985-144577 19850703
JP 1985-144578 19850703
JP 1985-163057 19850725

IT **26615-36-1**
RL: USES (Uses)
(fiber, biconstituent with synthetic fibers, fibrids, heat-resistant)

RN 26615-36-1 CAPLUS

CN Poly[(1-phenyl-1H-benzimidazole-2,5-diyl)iminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I, X=CH
II, X=N



III

AB Indole and benzimidazoleamidine derivs., including I (R = C(:NH)NH2, H; R1 = C(:NH)NH2, H, or NO2), II (R = C(:NH)NH2, CN, or C(:NH)OEt; R1 = C(:NH)NH2, H, CN, or C(:NH)NH2), and III (R = C(:NH)NH2, CN, or C(:NH)OEt) were synthesized by previously reported methods. On screening for antimalarial activity in mice infected with Plasmodium berghei, I; (R = 5-C(:NH)NH2; R1 = 4'-C(:NH)NH2) [66639-01-8] and II; (R = 5(6)-C(:NH)NH2; R1 = 4-C(:NH)NH2) [66639-16-5] had better antimalarial activity than the other synthesized compds. tested; however, the antimalarial effect of these 2 compds. was lower than the previously tested antimalarial agent, 4',6-diamidinyl-2-phenylimidazole.

ACCESSION NUMBER: 1986:101983 CAPLUS
DOCUMENT NUMBER: 104:101983
TITLE: Synthesis and antimalarial activity of some indole and benzimidazole amidine derivatives
AUTHOR(S): Zhang, Xiuping; Chen, Gendi; Xie, Xiaoyun
CORPORATE SOURCE: Shanghai Inst. Pharm. Ind., Shanghai, Peop. Rep. China
SOURCE: Yiyao Gongye (1985), 16(9), 394-9
CODEN: YIGODN; ISSN: 0255-7223
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

IT **100562-31-0P 100562-55-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 100562-31-0 CAPLUS
CN 1H-Benzimidazole-5-carboximidic acid, 2-[4-(ethoxyiminomethyl)phenyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 100562-55-8 CAPLUS
CN 1H-Benzimidazole-5-carboximidic acid, 2-[4-(ethoxyiminomethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 44 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Fused-ring imidazoles I [1-3 of X-X3 = R4N, the remainder = CO, R5C; R4 = H, alkyl; R5 = alkoxy, PhCH2O, HO, halo; R1 = alkyl, alkoxy, PhCH2O, R6S(O)n, halo, amino, NO2, CO2H, alkanamido, acyl (e.g., cyano, carbamoyl, sulfamoyl, alkoxycarbonyl); R2, R3 = H, alkyl, alkoxy, OH, R6S(O)n, amino, halo, NO2, alkanamido, acyl; R6 = alkyl; n = 0-2] were prepd. Thus, 2,4-(MeO)(MeS)C6H3CO2H and 4,5-diamino-3(2H)-pyridazinone were heated 90 min at 100-110.degree. in polyphosphoric acid to give 12% imidazopyridazinone II. In cats 2.0 mg II/kg gave a 72% increase in the heart contractility parameter and increased arterial blood pressure 10%.

ACCESSION NUMBER: 1986:5871 CAPLUS
DOCUMENT NUMBER: 104:5871
TITLE: 2-Phenylimidazoles and a drug containing these compounds
INVENTOR(S): Austel, Volkhard; Heider, Joachim; Hauel, Norbert; Reiffen, Manfred; Nickl, Josef; Van Meel, Jakobus C. A.; Diederen, Willi
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 66 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3347290	A1	19850711	DE 1983-3347290	19831228
ES 537992	A1	19851101	ES 1984-537992	19841127
DK 8406102	A	19850629	DK 1984-6102	19841219
EP 149200	A1	19850724	EP 1984-116009	19841220
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4722929	A	19880202	US 1984-684052	19841220
JP 60172980	A2	19850906	JP 1984-281991	19841225
FI 8405117	A	19850629	FI 1984-5117	19841227
NO 8405252	A	19850701	NO 1984-5252	19841227
DD 231355	A5	19851224	DD 1984-271864	19841227
HU 37618	A2	19860123	HU 1984-4843	19841227
ZA 8410057	A	19860924	ZA 1984-10057	19841227
AU 8437211	A1	19850704	AU 1984-37211	19841228
ES 543082	A1	19860101	ES 1985-543082	19850513
ES 543083	A1	19860101	ES 1985-543083	19850513
ES 543084	A1	19860101	ES 1985-543084	19850513
ES 543085	A1	19860101	ES 1985-543085	19850513
ES 543086	A1	19860101	ES 1985-543086	19850513

PRIORITY APPLN. INFO.: DE 1983-3347290 19831228

OTHER SOURCE(S): CASREACT 104:5871
IT **99445-95-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antihypotensive and inotropic agent)
RN 99445-95-1 CAPLUS
CN Benzamide, 4-(4,5-dihydro-4-oxo-1H-imidazo[4,5-c]pyridin-2-yl)-3-methoxy-
(9CI) (CA INDEX NAME)



L4 ANSWER 45 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Dibenzodiazocines I (NR2 = 4-methyl-1-piperazinyl, 4-morpholinyl, 4-carbethoxy-1-piperazinyl; R1 = H, Me) were prepd. Dibenzodiazocinedione II was heated with 1-methylpiperazine, TiCl4, and PhOMe to give I (NR2 = 4-methyl-1-piperazinyl, R1 = H).

ACCESSION NUMBER: 1985:560482 CAPLUS
DOCUMENT NUMBER: 103:160482
TITLE: Titanium tetrachloride-induced functionalization of dibenzo[b,f][1,4]diazocine-6,11-(5H,12H)-diones
AUTHOR(S): Venugopalan, Bindumadhavan; Iyer, Sivasailam Suresh; De Souza, Noel John
CORPORATE SOURCE: Res. Cent., Hoechst India Ltd., Bombay, 400 080, India
SOURCE: Heterocycles (1985), 23(6), 1425-30
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:160482

IT **98096-47-0P 98096-81-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 98096-47-0 CAPLUS
CN Piperazine, 1-methyl-4-[2-(5-nitro-1H-benzimidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



RN 98096-81-2 CAPLUS
CN Piperazine, 1-methyl-4-[2-(5-methyl-1H-benzimidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)


Me
H
N
N
C
O
N
N
Me

L4 ANSWER 46 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



I



II

AB Antihypertensive and inotropic fused-ring imidazoles I (R = substituted Ph; R1R2 = CH:CHCH:N, CH:NCH:N, substituted CH:CHCH:CH) were prepd. Thus, 2,4-(MeO)(PhCH2O)C6H3CO2H was cyclocondensed with C6H4(NH2)2-1,2 to give 53% II (R3 = PhCH2). This was hydrogenolized over Pd/C to give 95.8% II (R3 = H), which was esterified with MeSO2Cl to give 41.9% II (R3 = MeSO2) (III). In cats 2 mg III/kg had a contractility parameter dp/dtmax of 94 and reduced blood pressure 24 mm.

ACCESSION NUMBER: 1984:139110 CAPLUS
DOCUMENT NUMBER: 100:139110
TITLE: Imidazole derivatives and a pharmaceutical containing these compounds
INVENTOR(S): Hauel, Norbert; Austel, Volkhard; Heider, Joachim; Reiffen, Manfred; Diederen, Willi
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 63 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3224512	A1	19840105	DE 1982-3224512	19820701
FI 8302022	A	19840102	FI 1983-2022	19830606
EP 98448	A2	19840118	EP 1983-106026	19830621
EP 98448	A3	19850403		
R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
US 4582837	A	19860415	US 1983-506454	19830621
SU 1316559	A3	19870607	SU 1983-3606327	19830621
CS 254319	B2	19880115	CS 1983-4724	19830627
NO 8302356	A	19840102	NO 1983-2356	19830629
DD 210271	A5	19840606	DD 1983-252527	19830629
DK 8303013	A	19840102	DK 1983-3013	19830630
AU 8316428	A1	19840105	AU 1983-16428	19830630
GB 2122995	A1	19840125	GB 1983-17732	19830630
GB 2122995	B2	19860212		
JP 59027875	A2	19840214	JP 1983-119476	19830630
HU 31210	O	19840428	HU 1983-2382	19830630
HU 192152	B	19870528		
ES 523709	A1	19841001	ES 1983-523709	19830630
ZA 8304777	A	19850327	ZA 1983-4777	19830630
PL 142880	B1	19871231	PL 1983-242770	19830630
PL 144589	B1	19880630	PL 1983-260157	19830630
ES 529174	A1	19841001	ES 1984-529174	19840126
ES 529175	A1	19841001	ES 1984-529175	19840126
SU 1179924	A3	19850915	SU 1984-3699112	19840201
US 4696931	A	19870929	US 1985-728754	19850430

PRIORITY APPLN. INFO.: DE 1982-3224512 19820701
US 1983-506454 19830621
OTHER SOURCE(S): CASREACT 100:139110
IT **89454-65-9P 89454-66-0P 89469-11-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 89454-65-9 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 89454-66-0 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 89469-11-4 CAPLUS
CN Benzamide, 3-methoxy-N-methyl-4-(1H-purin-8-yl)- (9CI) (CA INDEX NAME)



IT **89454-64-8P 89469-10-3P 89469-25-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., antihypertensive, and inotropic activity of)
RN 89454-64-8 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 89469-10-3 CAPLUS
CN Benzamide, 3-methoxy-4-(1H-purin-8-yl)- (9CI) (CA INDEX NAME)



RN 89469-25-0 CAPLUS
CN Benzamide, 4-(1H-imidazo[4,5-b]pyridin-2-yl)-3-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 47 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB A series of copolymers contg. benzimidazole/benzamide, benzimidazole/benzimide, and benzimidazole/benzimidazolone repeat units were synthesized by condensation reactions and evaluated for their thermooxidative stabilities and soly. properties. Each copolymer exhibited the soly. characteristics of its least sol. component. Thus the benzimidazole/benzamides and the benzimidazole/benzimidazolones were insol. in Me2SO and AcNMe2. Relative stabilities to the early stages of thermooxidative degrdn. of the benzimidazole/benzamides and the benzimidazole/benzimide copolymers were compared by IR monitoring of isothermally aged (350.degree.) films. They ranged from comparable to slightly superior to benzimidazole homopolymer. Relative thermooxidative stabilities of the benzimidazole/benzimidazolone copolymer and the benzimidazole (PBI) and benzimidazolone (BBB) homopolymers were compared by similar monitoring of films cast from H2SO4. The PBI/BBB copolymer is comparable to but less stable than BBB homopolymer and considerably superior to PBI homopolymer.

ACCESSION NUMBER: 1980:586850 CAPLUS
DOCUMENT NUMBER: 93:186850
TITLE: Synthesis and thermooxidative properties of a series of benzimidazole copolymers
AUTHOR(S): Kane, J. J.; Lu, S. L.; Ghosh, S.; Bashe, J.; Conley, R. T.
CORPORATE SOURCE: Dep. Chem., Wright State Univ., Dayton, OH, 45435, USA
SOURCE: Polymer Preprints (American Chemical Society, Division of Polymer Chemistry) (1978), 19(1), 660-7
CODEN: ACPPAY; ISSN: 0032-3934
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **75236-89-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and thermal oxidative properties of)

RN 75236-89-4 CAPLUS

CN Poly([5,5'-bi-1H-benzimidazole]-2,2'-diyl-1,4-phenylenecarbonylimino-1,3-phenyleneiminocarbonyl-1,4-phenylene) (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L4 ANSWER 48 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI



AB .beta.-Lactams I and II (R = Q, Q1; R1 = optionally substituted Ph, monocyclic arom. heterocyclic, dihydrophenyl; R2 = H, OAc, heterocyclylthio; R3 = H, lower alkyl; R4 = H, optionally substituted alkyl, aryl, or heterocyclic; R5 = H, halogen, lower alkyl, alkoxy; X = CH, N; X1 = bond, CH2O; X2 = bond, C6H4; X3 = bond, lower alkylene, oxyalkylene) were prepd. Thus, 3.5 g ampicillin was treated with 2.93 g 2-phenyl-5-benzimidazolecarbonyl chloride-HCl to give 4.2 g I (R = 2-phenyl-5-benzimidazolecarbonyl, R1 = Ph).

ACCESSION NUMBER: 1978:424333 CAPLUS
DOCUMENT NUMBER: 89:24333
TITLE: .beta.-Lactam compounds
INVENTOR(S): Schorr, Manfred; Schrinner, Elmar; Worm, Manfred; Schmitt, Wilfried
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 78 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2641060	A1	19780316	DE 1976-2641060	19760911

PRIORITY APPLN. INFO.: DE 1976-2641060 19760911

IT **66631-31-0P 66631-82-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 66631-31-0 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[4-(1H-benzimidazol-2-yl)benzoyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

RN 66631-82-1 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[[[4-(1H-benzimidazol-2-yl)benzoyl]amino]phenylacetyl]amino]-8-oxo-, [6R-[6.alpha.,7.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 49 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB Polymers for medical use (polyesters, polyamides, polyimides, poly(vinyl chloride) [9002-86-2] and silicone rubber) were implanted s.c. into dogs or were immersed in a buffer soln. (pH 7.4) at 37.degree. for 26 months. No changes were obsd. in both treatments as detd. by differential interference microscopy, x-ray diffractometry, viscometry and IR spectroscopy. However, some additives were released by the poly(vinyl chloride) prepns.

ACCESSION NUMBER: 1977:444211 CAPLUS
DOCUMENT NUMBER: 87:44211
TITLE: Interaction between polymeric materials and tissue
AUTHOR(S): Kojima, Kohichi; Imai, Yohji; Masuhara, Eiichi
CORPORATE SOURCE: Inst. Med. Dent. Eng., Tokyo Med. Dent. Univ., Tokyo, Japan
SOURCE: Kobunshi Ronbunshu (1977), 34(4), 267-73
CODEN: KBRBA3; ISSN: 0386-2186
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

IT **26615-36-1**
RL: PRP (Properties)
(stability of, as prosthetics, in tissues)

RN 26615-36-1 CAPLUS
CN Poly[(1-phenyl-1H-benzimidazole-2,5-diyl)iminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)



L4 ANSWER 50 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB Polyoxadiazole fibers and films were manufd. by extruding a soln. of 2-15% resin in 75-110% H2SO4 optionally contg. .gtoreq.1 inorg. salt into a coagulation bath contg. an aq. soln. of H2SO4, a lower aliphatic carboxylic acid, and(or) a mixt. of these acids with .gtoreq.1 inorg. acids and amide compds., washing the fibers or films with water and then contacting them with buffer soln., amine, amide, or a salt of a weak acid or a metal hydroxide. For example, a soln. of polyoxadiazole [26023-46-1] resin in fuming H2SO4 (prepd. by reacting terephthalic acid, and hydrazine sulfate, in fuming H2SO4) was dild. with 95% H2SO4 at 80.degree. to obtain 4% soln. with a viscosity of 2500 P. The resin soln. was extruded into a 54% aq. soln. of H2SO4 at 62.degree. and coagulated at a linear velocity of 5.5 m/min. The coagulated filament was treated in a water bath for 10 min, an aq. NaOH [141-43-5] soln., another water bath, and drawn 3 times its original length and dried. The resulting filaments had a fineness of 7.2 denier, tenacity 3.6 g/denier, breaking elongation 50% and a Young's modulus 72 g/denier. They showed no change in tenacity after heating at 350.degree. in air for 10 hr and at 200.degree.for 5000 hr.

ACCESSION NUMBER: 1975:533210 CAPLUS
DOCUMENT NUMBER: 83:133210
TITLE: Forming polyoxadiazole series resin solution into shaped articles
INVENTOR(S): Sekiguchi, Hideo; Sadamitsu, Kazuo
PATENT ASSIGNEE(S): Furukawa Electric Co., Ltd., Japan
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3886251	A	19750527	US 1973-393978	19730904
JP 52000062	B4	19770105	JP 1967-23982	19670415
JP 52021014	B4	19770608	JP 1967-23981	19670415

PRIORITY APPLN. INFO.:
JP 1967-22981 19670411
JP 1967-22984 19670411
JP 1967-23981 19670415
JP 1967-23982 19670415
US 1968-717961 19680401
US 1972-313797 19721211

IT **29188-82-7P**
RL: PREP (Preparation)
(fiber and films, gelled state treatment by buffer and basic compds. in manuf. of, for improved thermal stability)

RN 29188-82-7 CAPLUS
CN Poly[(5,5'-bi-1H-benzimidazole]-2,2'-diyl-1,4-phenylenecarbonylhydrazocarbonyl-1,4-phenylene) (9CI) (CA INDEX NAME)



L4 ANSWER 51 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB Gelled, swollen polyoxadiazole fibers and films were made by successively contacting the cyclic arom. dicarboxylic acid-hydrazine deriv. copolymers with aq. H2SO4, water, aq. base or Mg salt, and water, so that the articles had good mech. strength and resistance to humidity. Thus hydrazine sulfate-4,4'-oxydibenzoic acid copolymer [54547-58-9] (prepd. in the presence of H2SO4.SO3) was poured on a glass plate coagulated in aq. H2SO4, and contacted with aq. NaHCO3 followed by water to give a swollen gelled film with elongation at break 124% and tensile strength 1.040 kg/cm2. The sample and one with the same mech. properties which had not been treated with aq. NaHCO3 were heated 4 weeks at 180.degree. to give products with resp. elongation at break 48 and 16% and resp. tensile strength 1050 and 620 kg/cm2.

ACCESSION NUMBER: 1975:480629 CAPLUS
DOCUMENT NUMBER: 83:80629
TITLE: Poly(1,3,4-oxadiazole) resin articles
INVENTOR(S): Sekiguchi, Hideo; Sadamitsu, Kazuo; Oda, Junichiro; Hirasa, Katsuyoshi
PATENT ASSIGNEE(S): Furukawa Electric Co., Ltd., Japan
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2228809	A1	19741206	FR 1974-15775	19740507
FR 2228809	B1	19800425		
GB 1422177	A	19760121	GB 1973-21780	19730508
AU 7468136	A1	19751023	AU 1974-68136	19740422
IT 1017586	A	19770810	IT 1974-22419	19740508

PRIORITY APPLN. INFO.: GB 1973-21780 19730508

IT **29188-82-7**
RL: USES (Uses)
(fiber)

RN 29188-82-7 CAPLUS

CN Poly[(5,5'-bi-1H-benzimidazole]-2,2'-diyl-1,4-phenylenecarbonylhydrazocarbonyl-1,4-phenylene) (9CI) (CA INDEX NAME)



L4 ANSWER 52 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB The model reactions between phthalic anhydride (I) [85-44-9] and o-phenylenediamine (II) [95-54-5] were studied under conditions analogous to the polymn. and postcyclization of dianhydrides with bis(o-diamines) to form poly(imidazopyrrolone). Thus, I was condensed with II in DMF to give 80% N-(o-aminophenyl) phthalamic acid (III) [7297-65-6] which when stored in aq. DMF gave a 2:1 mixt. of N-(o-aminophenyl) phthalimide (IV) [4506-62-1] and 2-(o-carboxyphenyl) benzimidazole (V) [16529-06-9]. Sublimation of IV at 200.deg. gave 11H-isoindolo[2,1.alpha.] benzimidazol-11-one (VI). O-phenylenebibenzimidazole and N,N'-diphthaloyl-o-phenylenediamine were obtained as by-products of the melt reaction of I and II. When 10% III in DMF was heated at 152-4.deg. it gave IV and V. When III was melted at 155.deg. it gave 36% V, 19% VI, and a benzimidazole-amide-imide (VII) [**35411-16-6**]. The IR spectra of the model compds. are given.

ACCESSION NUMBER: 1972:448851 CAPLUS
DOCUMENT NUMBER: 77:48851
TITLE: Poly(imidazopyrrolone) model compounds
AUTHOR(S): Young, Philip R.
CORPORATE SOURCE: Langley Res. Cent., NASA, Hampton, VA, USA
SOURCE: Journal of Heterocyclic Chemistry (1972), 9(2), 371-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English

L4 ANSWER 53 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB Poly(amide amines) (I) are ring-closed by the heat treatment to give heat-resistant polybenzimidazoles (II), which are sol. in polar org. solvents and useful as fibers and films. E.g., 2.72 g 2,4-diaminodiphenylamine-2HCl, 4.24 g Na2CO3, 50 ml H2O, and 42 ml THF (III) are stirred rapidly in a blender and the soln. is mixed with 2.03 g terephthaloyl chloride in 17 ml III and stirred 10 hr to give I (yellow powder), which is heated 6 hr at 300.degree. in vacuo to give II, which is sol. in HCO2H, dichloroacetic acid, and m-cresol, and shows thermal stability at .ltoreq.430.degree..

ACCESSION NUMBER: 1970:488408 CAPLUS
DOCUMENT NUMBER: 73:88408
TITLE: Manufacturing polybenzimidazoles
INVENTOR(S): Hara, Shigeyoshi; Seo, Masao; Uchida, Moriya
PATENT ASSIGNEE(S): Teijin Ltd.
SOURCE: Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 45022555	B4	19700730	JP	19671019

IT **26615-36-1P**
RL: PREP (Preparation)
(prepn. of)
RN 26615-36-1 CAPLUS
CN Poly[(1-phenyl-1H-benzimidazole-2,5-diyl)iminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN

AB A poly(oxadiazole) prepd. from terephthalic acid and hydrazine sulfate in fuming H2SO4 is treated with iso-Pr2SO4, PrOH, Et2SO4, propylene, or a similar compd. in H2SO4 to form N-alkylhydrazide units in the polymer chains. These modified polymers exhibit good soly. in org. solvents and are fusible, making them easier to handle than the untreated, infusible, insol. poly(oxadiazoles). After molding or extrusion, the modified polymers are heated (>200.degree.) to form oxadiazole rings from the N-alkylhydrazide units and are used in laminates.

ACCESSION NUMBER: 1970:467218 CAPLUS
DOCUMENT NUMBER: 73:67218
TITLE: Stable high temperature resins with N-alkylhydrazide structural units
INVENTOR(S): Sekiguchi, Hideo; Sadamitsu, Kazuo
PATENT ASSIGNEE(S): Furukawa Electric Co., Ltd.
SOURCE: Ger. Offen., 33 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1902591		19700702		

PRIORITY APPLN. INFO.: JP 19680122

IT **29188-82-7**
RL: USES (Uses)
(polyoxadiazoles from, conversion to poly(alkylhydrazides) for processing and regeneration of polyoxadiazoles)

RN 29188-82-7 CAPLUS

CN Poly[(5,5'-bi-1H-benzimidazole]-2,2'-diyl-1,4-phenylenecarbonylhydrazocarbonyl-1,4-phenylene) (9CI) (CA INDEX NAME)



L4 ANSWER 55 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI For diagram(s), see printed CA Issue.
AB Title compds. having the general formula I are prepd. by condensing (COCl)2 with 1-aminoanthraquinone (II) or substituted II to form the monoamide, which is then condensed with 1,2-diaminoanthraquinone (III) or substituted III. Thus, 8 parts finely powd. II was slowly added to stirred mixt. of p-C6H4(COCl)2 (IV) and 80 parts dry PhNO2 at 80.degree., the mixt. held at 95-100.degree. until no II could be detected (.apprx.2 hrs.), chilled, filtered, and washed with PhNO2 to give 1-[p-(chlorocarbonyl)-benzamido]anthraquinone (V), yellow crystals. To a soln. of 3.6 parts III in 100 parts dry PhNO2 at 120.degree. was added 0.5 part dry pyridine and 5.9 parts V, the mixt. heated in 40 min. to 180-90.degree., and stirred for 1 hr. at 180-90.degree. and for 1 hr. at 200-10.degree. to give I (X = p-C6H4, Y = Z = H), fine needles, greenish yellow on cotton. Similarly, other I were prepd. (X, Y, Z, and shade on cotton given): 2,5,1,4-Cl2C6H2, H, H, orange; p-C6H4, H, NHCOC6H4COCl, orange; p-C6H4, H, OMe, orange; 2,5-thiophenediyl, H, H, yellow; 4-C6H4C6H4-4, H, H, yellow; p-C6H4, Br, H, yellow; 2,5-pyridinediyl, H, H, greenish yellow. Similarly, VI and III gave a green dye.
ACCESSION NUMBER: 1966:491179 CAPLUS
DOCUMENT NUMBER: 65:91179
ORIGINAL REFERENCE NO.: 65:17096a-d
TITLE: Anthraquinone-imidazole vat dyes
PATENT ASSIGNEE(S): CIBA Ltd.
SOURCE: 19 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 668789		19660225	BE	
PRIORITY APPLN. INFO.:			CH	19640826

IT **10252-08-1**, 1H-Anthra[1,2-d]imidazole-6,11-dione, 2-[p-(1-anthraquinonylcarbamoyl)phenyl]- **10252-24-1**, 1H-Anthra[1,2-d]imidazole-6,11-dione, 2-[p-(2-anthraquinonylcarbamoyl)phenyl]- **13018-02-5**, 1H-Anthra[1,2-d]imidazole-6,11-dione, 2-[4-(1-anthraquinonylcarbamoyl)-2,5-dichlorophenyl]-
(prepn. of)
RN 10252-08-1 CAPLUS
CN Benzamide, N-(9,10-dihydro-9,10-dioxo-1-anthracenyl)-4-(6,11-dihydro-6,11-dioxo-1H-anthra[1,2-d]imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 10252-24-1 CAPLUS
CN Benzamide, N-(9,10-dihydro-9,10-dioxo-2-anthracenyl)-4-(6,11-dihydro-6,11-dioxo-1H-anthra[1,2-d]imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 13018-02-5 CAPLUS
CN 1H-Anthra[1,2-d]imidazole-6,11-dione, 2-[4-(1-anthraquinonylcarbamoyl)-2,5-dichlorophenyl]- (7CI, 8CI) (CA INDEX NAME)



L4 ANSWER 56 OF 56 CAPLUS COPYRIGHT 2003 ACS on STN
GI For diagram(s), see printed CA Issue.
AB cf. CA 62, 13253a; 63, 4405f. One mole PhOH in 80 ml. C5H5N was added dropwise to 1.1 mole isophthaloyl chloride (I) in 800 ml. anhyd. C6H6, refluxed for 2 hrs., filtered, the ppt. treated with 500 ml. boiling C6H6, filtered and the 2 filtrates combined and evapd. The residue was fractionally distd. to give a 38% yield of Ph m-chloroformylbenzoate (II), b0.5 162.degree., m. 69-70.degree.. Bis[4-(phenoxycarbonyl)-phenyl]-N,N'-isophthalamide (III), m. 301.degree., was prepd. in 60% yield by adding 0.015 mole I in 20 ml. AcNMe2 to 0.03 mole Ph p-aminobenzoate (IV), 9 ml. Et3N, and 60 ml. AcNMe2 at -15.degree., stirring 10 min. at -15.degree. and 45 min. at room temp., filtering the ppt. of Et3N.HCl, pptg. III from the filtrate with 500 ml. H2O, drying, and recrystg. from a mixt. of EtOH and HCONMe2. Similarly, bis(3-phenoxycarbonylphenyl)-N,N'-isophthalamide (V), m. 219.degree., bis[N-(4-phenoxycarbonylphenyl)-4-carbamoylphenyl] ether, m. 325.degree., and bis[N-(3-phenoxycarbonylphenyl)-4-carbamoylphenyl]ether, m. 199.degree., were prepd. from I and Ph m-aminobenzoate (VI), bis(4-chloroformylphenyl) ether (VII), and IV, and VI and VII, resp. VII, m. 81.degree., was prepd. by the method of Bosshard (CA 54, 3296b). Likewise, 1,3-bis(3-phenoxycarbonylbenzoylamino)benzene (VIII), m. 253.degree., and bis[4-(3-phenoxycarbonylbenzoylamino)phenyl]ether (IX), m. 283.degree., were prepd. in 65% yield by recrystn. from PhNO2 by the condensation of m-phenylenediamine (X) and II, and 4,4'-diaminodiphenyl ether (XI) and II, resp. The melting together of 1 g. VIII and 1 g. o-phenylenediamine (XII) in vacuo for 45 min. at 250.degree. and 1 hr. at 300.degree., washing of the product with Et2O, treatment with boiling PhNO2, and washing again with Et2O, gave a 46% yield of m-bis[3-(2-benzimidazolyl)benzoylamino]benzene, m. 357.degree.. Similarly, bis[4-[3-(2-benzimidazolyl)benzoylamino]phenyl] ether, m. 391.degree., was obtained in 47% yield by recrystn. from HOAc from 2.16 g. IX and 1.5 g. XII. Polymers XIII-XV were prepd. XIII was prepd. by melting together 1.853 g. (XV) VIII and 0.71 g. 3,3'-diaminobenzidine (XVI) at 300.degree. and heating for 5 hrs. at 300-400.degree.. Similarly, XIV was prepd. from 2.16 g. IX and 0.71 g. XVI, and XV from 4.77 g. V and 1.83 g. XVI. XIII was also prepd. by dissolving 4.77 g. VIII in 15 ml. Me2SO at 120-70.degree. in an inert atm., adding 1.83 g. XVI, refluxing at 180-200.degree. for 2.25 hrs., distg. the solvent, and heating the residue for 1 hr. at 250-300.degree., and then in vacuo at 300-80.degree. for 3.5 hrs. Inherent viscosity at 0.5% in concd. H2SO4 at 30.degree. was 0.24, 0.19, and 0.20 for XIII, XIV, and XV, resp. The ir and uv spectra showed the disappearance of the CO and ester groups, and the appearance of the benzimidazole group. Similar unordered polymers were obtained by melting together Ph isophthalate, PhOLi, and XVI with either X or XI and heating in vacuo at 300-400.degree.. In thermal stability testing at a 60.degree./hr. temp. rise, all 3 polymers showed a start of wt. loss in Ar and air at 400.degree., reaching 10 and 25-50% loss at 500.degree. in Ar and air, resp.

ACCESSION NUMBER: 1966:104885 CAPLUS
DOCUMENT NUMBER: 64:104885
ORIGINAL REFERENCE NO.: 64:19810c-h,19811a
TITLE: Thermostable polymers. IV. Poly(amide benzimidazoles)
AUTHOR(S): Rabilloud, Guy; Sillion, Bernard; Gaudemaris, Gabriel de
CORPORATE SOURCE: Inst. Francais Petrole, Grenoble, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1966), (3), 926-32
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French

IT **7522-68-1**, Benzamide, N,N'-m-phenylenebis[3-(2-benzimidazolyl)-

7522-69-2, Benzamide, N,N'-(oxydi-p-phenylene)bis[3-(2-benzimidazolyl)-
(prepn. of)
RN 7522-68-1 CAPLUS
CN Benzamide, N,N'-m-phenylenebis[3-(2-benzimidazolyl)- (7CI, 8CI) (CA INDEX NAME)



RN 7522-69-2 CAPLUS
CN Benzamide, N,N'-(oxydi-p-phenylene)bis[3-(2-benzimidazolyl)- (7CI, 8CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



```
=> d his

     (FILE 'HOME' ENTERED AT 09:43:19 ON 31 JUL 2003)

     FILE 'REGISTRY' ENTERED AT 09:43:33 ON 31 JUL 2003
L1              STRUCTURE UPLOADED
L2            7 S L1
L3          907 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 09:47:11 ON 31 JUL 2003
L4           56 S L3

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     253.98     404.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -36.46     -36.46

STN INTERNATIONAL LOGOFF AT 09:50:26 ON 31 JUL 2003
```

C:\Program Files\Stnexp\Queries\10019105.str





chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
13
chain bonds :
8-10 10-11 11-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 10-11 11-12 11-13

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS